{"gene":"TP53","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1991,"finding":"p53 mutations occur in diverse human tumor types and are concentrated in four highly conserved regions of the DNA-binding domain, with mutational spectra that differ by tumor type and correlate with carcinogen exposure (e.g., G:C to T:A transversions in lung/liver cancers, C-to-T transitions at CpG hotspots in colon/brain tumors, codon 249 hotspot in aflatoxin-associated liver cancer).","method":"Direct DNA sequencing across multiple tumor types","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — landmark multi-tumor sequencing study, independently replicated across labs; foundational paper with >7000 citations","pmids":["1905840","2531845"],"is_preprint":false},{"year":1994,"finding":"The crystal structure of the p53 core domain (residues 102–292) bound to DNA revealed a β-sandwich scaffold supporting two large loops (held together by a zinc atom) and a loop-sheet-helix motif that forms the DNA-binding surface; tumor-derived mutations cluster in these conserved structural elements, explaining their loss of DNA-binding activity.","method":"X-ray crystallography at 2.2 Å resolution; structural analysis of tumor mutant positions","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with direct mechanistic interpretation of mutant residues; >2200 citations","pmids":["8023157"],"is_preprint":false},{"year":1990,"finding":"HPV-16 and HPV-18 E6 oncoproteins physically associate with the p53 tumor suppressor protein; this interaction correlates with the transforming activity of different HPV types, providing a mechanism for viral inactivation of p53.","method":"Co-immunoprecipitation / in vitro binding assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — direct binding demonstrated in multiple assays, replicated; >2300 citations","pmids":["2157286"],"is_preprint":false},{"year":1993,"finding":"The HPV E6–E6AP complex functions as a ubiquitin-protein ligase (E3) that ubiquitinates p53, targeting it for proteasomal degradation; E6AP itself possesses intrinsic ubiquitin ligase activity independent of E6.","method":"In vitro ubiquitination reconstitution with purified E1, E2, E6, E6-AP and p53","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — fully reconstituted in vitro E3 ligase activity with purified components; >2000 citations","pmids":["8221889"],"is_preprint":false},{"year":1992,"finding":"MDM2 protein binds directly to p53 in vitro; the MDM2 gene is amplified in over one-third of human sarcomas, providing a mechanism for functional inactivation of p53 without mutation of TP53 itself.","method":"In vitro binding of recombinant proteins; Southern blot/gene amplification analysis of sarcoma samples","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct protein binding plus genomic amplification in tumors; >1900 citations","pmids":["1614537"],"is_preprint":false},{"year":1996,"finding":"Crystal structure of the MDM2 N-terminal domain bound to the p53 transactivation domain peptide revealed that p53 binds as an amphipathic α-helix inserting into a deep hydrophobic cleft on MDM2; three p53 residues (Phe19, Trp23, Leu26) make critical contacts, and this surface overlaps with p53's transactivation domain, explaining how MDM2 inhibits p53 transcriptional activity.","method":"X-ray crystallography of MDM2–p53 peptide complex","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — crystal structure defining the molecular interface; >1800 citations","pmids":["8875929"],"is_preprint":false},{"year":1997,"finding":"MDM2 is a ubiquitin ligase (E3) that polyubiquitinates p53 in the presence of E1 and UbcH5 (E2); a cysteine residue in the C-terminus of MDM2 is essential for this E3 activity, providing the primary mechanism for p53 proteasomal degradation in cells lacking viral E6.","method":"In vitro ubiquitination assay with purified recombinant proteins; cysteine mutagenesis","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro E3 ligase activity with mutagenesis confirmation; >1600 citations","pmids":["9450543"],"is_preprint":false},{"year":1997,"finding":"DNA damage-induced phosphorylation of p53 at Ser15 (and Ser37) by DNA-PK reduces p53's interaction with MDM2, thereby alleviating MDM2-mediated inhibition of p53 transcriptional activity; this phosphorylation induces a conformational change in p53.","method":"In vitro phosphorylation with purified DNA-PK; co-immunoprecipitation; transcription reporter assays in cells","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay plus cellular validation; >1700 citations","pmids":["9363941"],"is_preprint":false},{"year":1997,"finding":"p53 can be acetylated in vitro and in vivo by the coactivator p300 at C-terminal lysine residues; this acetylation dramatically stimulates p53 sequence-specific DNA-binding activity, indicating a novel activation pathway through acetylation-induced conformational change.","method":"In vitro acetylation assay with purified p300 and p53; DNA-binding EMSA; in vivo acetylation detection","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution plus functional DNA-binding assay; >2200 citations","pmids":["9288740"],"is_preprint":false},{"year":1997,"finding":"Oncogenic Ras expression in primary human or rodent cells induces a permanent G1 arrest (premature senescence) accompanied by accumulation of p53 and p16INK4a; inactivation of either p53 or p16 prevents this arrest, establishing that p53 is required for Ras-induced oncogene senescence.","method":"Retroviral expression of oncogenic Ras in primary cells; genetic inactivation of p53 and p16; cell cycle analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — epistasis with KO/KD plus phenotypic readout; >4200 citations","pmids":["9054499"],"is_preprint":false},{"year":1998,"finding":"ATM kinase is activated by ionizing radiation and directly phosphorylates p53 at Ser15 in a manganese-dependent manner; ionizing radiation (but not UV) rapidly enhances ATM's p53-directed kinase activity, and phosphorylation of p53 Ser15 is reduced in ataxia telangiectasia cells, establishing ATM as a kinase that phosphorylates p53 in vivo after ionizing radiation.","method":"In vitro kinase assay with immunoprecipitated ATM; phosphorylation mapping; ATM-deficient cell lines","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase reconstitution plus genetic validation in AT cells; >1700 citations","pmids":["9733515"],"is_preprint":false},{"year":2001,"finding":"hSIRT1 (hSIR2) binds p53 and deacetylates it in an NAD-dependent manner with specificity for Lys382; wild-type hSIRT1 expression reduces p53 transcriptional activity, while a catalytically inactive mutant potentiates p53-dependent apoptosis and radiosensitivity.","method":"Co-immunoprecipitation; in vitro deacetylase assay; transcription reporter assays; catalytic mutant expression","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro enzymatic assay plus cellular functional validation with catalytic mutant; >2200 citations","pmids":["11672523"],"is_preprint":false},{"year":2002,"finding":"HAUSP (herpesvirus-associated ubiquitin-specific protease) was identified by mass spectrometry as a p53-interacting protein; HAUSP specifically deubiquitinates p53 both in vitro and in vivo, stabilizing p53 even in the presence of excess MDM2 and inducing p53-dependent growth repression and apoptosis; a catalytically inactive HAUSP mutant increases p53 ubiquitination and destabilizes p53.","method":"Mass spectrometry of affinity-purified p53 complexes; Co-IP; in vitro deubiquitination assay; catalytic point mutant; cell growth/apoptosis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — MS identification, reconstituted DUB assay, catalytic mutant, functional rescue; >860 citations","pmids":["11923872"],"is_preprint":false},{"year":2004,"finding":"Small-molecule MDM2 antagonists (Nutlins) that bind the p53-binding pocket of MDM2 (confirmed by co-crystal structures) activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and inhibition of tumor xenograft growth in vivo.","method":"X-ray crystallography of MDM2–Nutlin complexes; cell-based p53 pathway activation; xenograft tumor growth inhibition","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of inhibitor complex plus in vivo functional validation; >3800 citations","pmids":["14704432"],"is_preprint":false},{"year":2004,"finding":"Cytosolic p53 directly activates the proapoptotic Bcl-2 protein Bax in the absence of other proteins, sufficient to permeabilize mitochondria and engage apoptosis; this transcription-independent mechanism operates similarly to BH3-only proteins and also releases Bcl-xL-sequestered proapoptotic factors.","method":"In vitro mitochondrial permeabilization assay with purified proteins; cytosolic fractionation; transcription-deficient p53 mutant analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro assay with purified p53 and Bax; transcription-independent mutant confirmation; >1600 citations","pmids":["14963330"],"is_preprint":false},{"year":2005,"finding":"p53 has an alternative internal promoter in intron 3 (conserved from Drosophila to humans) and produces multiple splice variants including p53β and Δ133p53; p53β can enhance p53 target gene expression in a promoter-dependent manner, while Δ133p53 acts as a dominant-negative inhibitor of full-length p53-mediated apoptosis.","method":"RT-PCR; reporter assays; antisense inhibition; expression in tumor vs. normal tissue","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 — functional characterization of isoforms with reporter assays and dominant-negative demonstration; >670 citations","pmids":["16131611"],"is_preprint":false},{"year":2007,"finding":"p53 transactivates miR-34a directly after DNA damage; miR-34a expression causes widespread reprogramming of gene expression enriched for cell-cycle, apoptosis, DNA repair, and angiogenesis genes, and promotes apoptosis, establishing miR-34a as a component of the p53 transcriptional network.","method":"Global miRNA expression profiling; promoter characterization; p53 ChIP; miR-34a overexpression with gene expression arrays; apoptosis assays","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct p53 binding to miR-34a promoter plus functional consequences; >1600 citations","pmids":["17540599"],"is_preprint":false},{"year":2010,"finding":"USP10, a cytoplasmic deubiquitinase, deubiquitinates p53 and reverses MDM2-induced p53 nuclear export and degradation; after DNA damage, USP10 is stabilized and a fraction translocates to the nucleus to activate p53; ATM phosphorylates USP10 at Thr42 and Ser337 to regulate this translocation and stabilization.","method":"Co-IP; in vitro deubiquitination assay; subcellular fractionation; ATM kinase assay; USP10 KD with p53 stability readouts","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro DUB assay, ATM phosphorylation site mapping, localization with functional consequence; >500 citations","pmids":["20096447"],"is_preprint":false},{"year":2010,"finding":"lincRNA-p21 is transcriptionally induced by p53 and serves as a transcriptional repressor in the p53 response; it physically associates with hnRNP-K, and this interaction is required for proper genomic localization of hnRNP-K at repressed genes; lincRNA-p21 knockdown de-represses hundreds of p53-repressed genes and reduces apoptosis.","method":"RNA-seq; RIP (RNA immunoprecipitation) for hnRNP-K; lincRNA-p21 knockdown with gene expression profiling; ChIP","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — direct RNA-protein interaction demonstrated by RIP, genomic localization by ChIP, KD with functional readout; >1700 citations","pmids":["20673990"],"is_preprint":false},{"year":2001,"finding":"p53DINP1, a p53-inducible nuclear protein, is required for Ser46 phosphorylation of p53 and for induction of p53AIP1 and apoptosis in response to DNA double-strand breaks; overexpression of p53DINP1 synergizes with DNA damage to enhance Ser46 phosphorylation; the protein complex associated with p53DINP1 can phosphorylate p53 at Ser46, placing p53DINP1 as a cofactor for the Ser46 kinase.","method":"Differential display; antisense oligonucleotide inhibition; overexpression; in vitro kinase assay with p53DINP1-associated complex","journal":"Molecular Cell","confidence":"Medium","confidence_rationale":"Tier 2 — kinase assay plus antisense KD functional phenotype; single lab but multiple methods","pmids":["11511362"],"is_preprint":false},{"year":2002,"finding":"E2F1, unlike E2F2, specifically signals p53 phosphorylation (modifications resembling DNA damage response) in a p19ARF-independent manner; this phosphorylation is required for E2F1-mediated apoptosis; caffeine (PI3K-related kinase inhibitor) abolishes both p53 phosphorylation and E2F1-mediated apoptosis, and co-expression of a p53 phosphorylation-site mutant compromises apoptosis.","method":"Adenoviral expression of E2F1 in p19ARF-null cells; Western blot for phospho-p53; apoptosis assays; caffeine inhibition; phospho-site mutant p53","journal":"Molecular and Cellular Biology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis plus pharmacological inhibition and phospho-site mutagenesis; single lab","pmids":["12101227"],"is_preprint":false},{"year":2013,"finding":"OTUD5, a deubiquitinase, interacts directly with p53 and deubiquitinates it; OTUD5 is required for rapid activation of p53-dependent transcription and p53-dependent apoptosis in response to DNA damage.","method":"Co-IP; in vitro deubiquitination assay; OTUD5 knockdown with p53 ubiquitination and apoptosis readouts","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 2 — direct DUB assay plus KD functional phenotype; single lab","pmids":["24143256"],"is_preprint":false},{"year":2014,"finding":"USP11, an ubiquitin-specific protease, forms a specific complex with p53 and stabilizes it by deubiquitination; USP11 knockdown markedly attenuates p53 induction in response to DNA damage.","method":"Co-IP; deubiquitination assay; USP11 knockdown with p53 stability readout","journal":"Journal of Zhejiang University. Science. B","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP and DUB assay with KD; single lab, limited functional follow-up","pmids":["25471832"],"is_preprint":false},{"year":2015,"finding":"p53 suppresses ferroptosis resistance by repressing SLC7A11 (a key component of the cystine/glutamate antiporter), thereby inhibiting cystine uptake and sensitizing cells to ferroptotic death under ROS stress; an acetylation-defective p53 mutant (3KR) that cannot induce cell-cycle arrest, senescence, or apoptosis retains this SLC7A11-repression activity and tumor suppressive function in xenograft models.","method":"ChIP; reporter assays; p53 3KR acetylation mutant; SLC7A11 overexpression rescue; xenograft tumor growth assays; ferroptosis cell death assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic dissection with separation-of-function mutant, ChIP, and in vivo rescue; >2700 citations","pmids":["25799988"],"is_preprint":false},{"year":2016,"finding":"NAT10 acetylates p53 at K120 and promotes p53 stabilization by counteracting MDM2; additionally, NAT10 promotes MDM2 degradation via its intrinsic E3 ligase activity; after DNA damage, NAT10 translocates from nucleolus to nucleoplasm to activate p53-mediated cell cycle control and apoptosis.","method":"Co-IP; in vitro acetylation assay; in vitro ubiquitination assay; subcellular fractionation/localization; KD with p53 target gene expression and cell cycle/apoptosis readouts","journal":"EMBO Reports","confidence":"Medium","confidence_rationale":"Tier 2 — multiple biochemical assays (acetylation, ubiquitination) plus localization with functional consequence; single lab","pmids":["26882543"],"is_preprint":false},{"year":2016,"finding":"Loss of TP53 and RB1 function enables lineage plasticity in prostate cancer through increased SOX2 expression, allowing tumor cells to shift from AR-dependent luminal to AR-independent basal-like phenotype; restoration of TP53 and RB1 function or SOX2 inhibition reverses this plasticity and restores drug sensitivity.","method":"In vitro and in vivo human prostate cancer models with TP53/RB1 knockout/restoration; SOX2 knockdown; lineage marker analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function/rescue in both cell and animal models with defined molecular mechanism; >870 citations","pmids":["28059768"],"is_preprint":false},{"year":2016,"finding":"The p53 isoform Δ133p53β promotes cancer cell invasion and EMT (epithelial-to-mesenchymal transition) regardless of TP53 mutation status; depletion of endogenous Δ133p53β prevents invasiveness without affecting full-length mutant p53 expression, explaining why wild-type TP53 can promote invasion in some contexts.","method":"Isoform-specific siRNA depletion; overexpression; invasion assays; EMT marker analysis in breast and colon cell lines","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific KD with defined phenotypic readout; multiple cell lines; single lab","pmids":["27630122"],"is_preprint":false},{"year":2019,"finding":"p53 is modified by β-hydroxybutyrylation (Kbhb) at Lys120, Lys319, and Lys370, catalyzed by CBP; p53 Kbhb results in reduced acetylation levels and decreased expression of p53 target genes (p21, PUMA), as well as reduced cell growth arrest and apoptosis; this mechanism is activated by elevated β-hydroxybutyrate (BHB) during starvation.","method":"Mass spectrometry identification of modification sites; CBP in vitro Kbhb assay; BHB treatment of cells and fasted mouse thymus; p53 target gene expression; apoptosis/growth arrest assays","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — novel PTM identified by MS, catalytic enzyme identified, functional consequence shown in cells and in vivo; single lab","pmids":["30858356"],"is_preprint":false},{"year":2019,"finding":"FBW7α targets p53 for proteasomal degradation via Lys-48-linked polyubiquitylation at Lys-132; this requires phosphorylation of p53 at Ser33 (by GSK3β) and Ser37 (by DNA-PK) creating a phosphodegron that enhances p53 binding to FBW7α; FBW7α-mediated degradation occurs during and after DNA double-strand breaks, and its abrogation enhances p53 tumor-suppressive function.","method":"Co-IP; in vitro ubiquitination assay; phospho-site mutagenesis; kinase inhibitor treatments; FBW7α domain mutants; DNA damage assays","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — phosphodegron identified with mutagenesis, E3 activity reconstituted, multiple orthogonal methods; single lab","pmids":["31346036"],"is_preprint":false},{"year":2021,"finding":"ZDHHC1 palmitoyltransferase palmitoylates p53 at Cys135, Cys176, and Cys275; this palmitoylation is required for nuclear translocation of p53; p53 in turn recruits DNMT3A to the ZDHHC1 promoter, creating an epigenetic feedback loop that silences ZDHHC1.","method":"Acyl-RAC palmitoylation assay; site-directed mutagenesis of cysteine residues; nuclear fractionation; ChIP for DNMT3A","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — palmitoylation identified and sites mapped by mutagenesis, nuclear localization consequence shown, feedback loop by ChIP; single lab","pmids":["34282274"],"is_preprint":false},{"year":2004,"finding":"p53 transactivates the MKP1 phosphatase through two p53 responsive elements—one in the second intron and a newly identified one in the third exon of MKP1; both elements bind p53 in vitro (gel shift) and in vivo (ChIP), and mutation of either element reduces reporter activity ~50% while loss of both completely abolishes p53-dependent MKP1 transcription.","method":"Reporter gene assays; EMSA (gel shift); ChIP; site-directed mutagenesis of p53 responsive elements","journal":"Cancer Biology & Therapy","confidence":"Medium","confidence_rationale":"Tier 2 — direct p53 binding to regulatory elements shown by EMSA and ChIP with mutagenesis; single lab","pmids":["15611668"],"is_preprint":false},{"year":2020,"finding":"A mouse model of the human TP53 R181C germline mutation (p53 R178C knockin) revealed a novel lipolytic activity of p53: mutant mice are lean with increased lipolysis and fatty acid metabolism in white adipose tissue; ChIP-seq showed mutant p53 bound and transactivated the ADRB3 (Beta-3-Adrenergic Receptor) gene, which promotes lipolysis.","method":"Knockin mouse model; body composition analysis; gene expression profiling; ChIP-seq","journal":"Cell Reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq direct binding evidence plus in vivo metabolic phenotype in knockin model; single lab","pmids":["31968253"],"is_preprint":false},{"year":2023,"finding":"The African-centric TP53 Y107H variant is structurally similar to wild-type p53 (by NMR and crystal structure) but is specifically impaired for transactivation of a small subset of target genes including PADI4; PADI4 (a citrullinating enzyme) is itself tumor suppressive and requires an intact immune system for this function; a p53-PADI4 gene signature predicts cancer survival and response to immune-checkpoint inhibitors.","method":"NMR structure; crystal structure; transcriptional reporter assays; Y107H knockin mouse tumor models; PADI4 KO mouse; immune depletion experiments","journal":"Cancer Discovery","confidence":"High","confidence_rationale":"Tier 1–2 — structural and functional characterization with in vivo tumor models and immune validation; multiple orthogonal methods","pmids":["37140445"],"is_preprint":false},{"year":2016,"finding":"An African-specific p53 variant S47 (Pro47Ser) shows selective impairment in transactivating metabolic target genes GLS2 and SCO2 and is markedly defective in inducing ferroptotic cell death; S47 mice develop spontaneous cancers of diverse histological types.","method":"Human cell lines and knockin mouse model; p53 target gene expression profiling; cell death assays with multiple genotoxic agents; ferroptosis assays","journal":"Genes & Development","confidence":"Medium","confidence_rationale":"Tier 2 — functional dissection of variant activity in cell lines and in vivo knockin model; single lab","pmids":["27034505"],"is_preprint":false},{"year":2001,"finding":"Deoxycholic acid (DCA) suppresses p53 protein levels by stimulating proteasome-mediated degradation via the nuclear export protein CRM1/ERK signaling pathway; this occurs post-transcriptionally (DCA actually induces p53 mRNA) and is blocked by the proteasome inhibitor lactacystin, CRM1 inhibitor leptomycin B, or ERK pathway inhibitors.","method":"HCT116 cell line; p53 mRNA vs. protein analysis; proteasome/CRM1/ERK inhibitors; p53 transcriptional activity assays","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological inhibitor approach without direct reconstitution; single lab with multiple inhibitors","pmids":["11375905"],"is_preprint":false}],"current_model":"p53 (TP53) is a tetrameric transcription factor whose core DNA-binding domain (stabilized by zinc and structured around a β-sandwich scaffold) binds specific response elements to activate or repress target genes governing cell cycle arrest, apoptosis (including direct cytosolic activation of Bax), senescence, ferroptosis (via SLC7A11 repression), and metabolic regulation; its activity is tightly controlled by a web of post-translational modifications—including MDM2-mediated ubiquitination (reversed by deubiquitinases HAUSP, USP10, USP11, OTUD5), p300/CBP-mediated acetylation at C-terminal and K120 lysines (reversed by SIRT1), damage-induced phosphorylation at Ser15/Ser37 by ATM and DNA-PK (disrupting MDM2 binding), and novel modifications including β-hydroxybutyrylation (by CBP) and palmitoylation (by ZDHHC1, required for nuclear localization); MDM2 serves as its primary E3 ligase and transcriptional inhibitor, itself antagonized by Nutlin-class small molecules; multiple isoforms (e.g., Δ133p53β, p53β) arising from alternative promoters differentially modulate full-length p53 activity; and HPV E6 hijacks the cellular E3 ligase E6AP to ubiquitinate and degrade p53 in virally-associated cancers."},"narrative":{"teleology":[{"year":1990,"claim":"Establishing that viral oncoproteins physically target p53 answered how DNA tumor viruses disable tumor suppression, linking p53 to the mechanism of HPV-driven carcinogenesis.","evidence":"Co-immunoprecipitation demonstrating direct HPV E6–p53 binding","pmids":["2157286"],"confidence":"High","gaps":["Mechanism of E6-mediated p53 degradation not yet defined","Whether E6 recruits a cellular ubiquitin ligase unknown"]},{"year":1991,"claim":"Systematic sequencing of TP53 across tumor types revealed that mutations concentrate in four conserved DNA-binding domain regions with carcinogen-specific spectra, establishing TP53 as the most broadly mutated gene in human cancer.","evidence":"Direct DNA sequencing of TP53 in diverse tumor panels","pmids":["1905840","2531845"],"confidence":"High","gaps":["Why specific codons are preferential hotspots not structurally explained","Functional consequence of individual mutations not biochemically tested"]},{"year":1992,"claim":"Discovery that MDM2 binds p53 directly and is amplified in sarcomas identified the principal cellular negative regulator of p53, explaining how tumors inactivate p53 without TP53 mutation.","evidence":"In vitro binding of recombinant proteins; Southern blot showing MDM2 amplification in sarcomas","pmids":["1614537"],"confidence":"High","gaps":["Whether MDM2 degrades p53 or only inhibits transactivation not distinguished","Structural basis of binding unknown"]},{"year":1993,"claim":"Reconstitution of the E6–E6AP ubiquitin ligase complex degrading p53 established the first defined proteolytic pathway targeting p53 and revealed E6AP as a cellular E3 ligase co-opted by HPV.","evidence":"In vitro ubiquitination with purified E1, E2, E6, E6AP, and p53","pmids":["8221889"],"confidence":"High","gaps":["Whether analogous cellular E3 ligases target p53 in the absence of virus unknown","In vivo degradation kinetics not measured"]},{"year":1994,"claim":"The crystal structure of the p53 core domain bound to DNA explained why cancer mutations cluster at DNA-contact residues and zinc-coordinating positions, transforming mutational data into a structural framework.","evidence":"X-ray crystallography at 2.2 Å resolution","pmids":["8023157"],"confidence":"High","gaps":["Structure of full-length tetrameric p53 not resolved","How mutations alter protein stability versus DNA contact not quantified"]},{"year":1996,"claim":"The MDM2–p53 co-crystal structure revealed that p53's transactivation helix inserts into a hydrophobic cleft on MDM2, explaining how MDM2 simultaneously blocks transcription and enabling structure-based drug design.","evidence":"X-ray crystallography of MDM2 N-terminal domain bound to p53 peptide","pmids":["8875929"],"confidence":"High","gaps":["Full-length MDM2–p53 complex structure unavailable","Whether disrupting this interface suffices for p53 activation in vivo untested"]},{"year":1997,"claim":"A suite of discoveries established the core regulatory logic of p53 activation: MDM2 was shown to be a direct E3 ubiquitin ligase for p53; DNA-damage-induced phosphorylation at Ser15/Ser37 by DNA-PK disrupts MDM2 binding; and p300-mediated acetylation of C-terminal lysines stimulates DNA binding — collectively defining the PTM code that toggles p53 between latent and active states.","evidence":"In vitro ubiquitination with MDM2 and cysteine mutagenesis; in vitro DNA-PK phosphorylation with MDM2 co-IP; in vitro p300 acetylation with EMSA","pmids":["9450543","9363941","9288740"],"confidence":"High","gaps":["Identity of the in vivo kinase for Ser15 (ATM vs DNA-PK) not resolved","Interplay between phosphorylation and acetylation not defined","Whether acetylation is required or merely potentiating in vivo unknown"]},{"year":1997,"claim":"Demonstration that oncogenic Ras triggers p53-dependent premature senescence in primary cells established senescence as a bona fide p53-mediated tumor-suppressive output distinct from apoptosis.","evidence":"Retroviral Ras expression in primary cells with p53 genetic inactivation","pmids":["9054499"],"confidence":"High","gaps":["Specific p53 target genes mediating senescence not identified","Relative contribution of p53 versus p16 not fully dissected"]},{"year":1998,"claim":"Identification of ATM as the ionizing-radiation-activated kinase that phosphorylates p53 Ser15 in vivo resolved the upstream kinase question and linked p53 activation to the DNA double-strand break signaling cascade.","evidence":"In vitro kinase assay with immunoprecipitated ATM; reduced Ser15 phosphorylation in ATM-deficient cells","pmids":["9733515"],"confidence":"High","gaps":["Whether ATM phosphorylates p53 directly or through intermediary kinases like Chk2 not fully resolved","UV-induced p53 activation pathway still undefined"]},{"year":2001,"claim":"Discovery that SIRT1 deacetylates p53 at Lys382 in an NAD-dependent manner established a metabolically-regulated brake on p53 activity, linking cellular metabolic state to tumor suppression.","evidence":"Co-IP; in vitro NAD-dependent deacetylase assay; catalytic-dead mutant enhancing p53-dependent apoptosis","pmids":["11672523"],"confidence":"High","gaps":["In vivo physiological contexts where SIRT1–p53 axis is rate-limiting not defined","Whether other sirtuins contribute to p53 deacetylation unknown"]},{"year":2002,"claim":"Identification of HAUSP as a deubiquitinase that stabilizes p53 even in the presence of excess MDM2 revealed that p53 levels are set by a balance between ubiquitination and deubiquitination rather than by MDM2 alone.","evidence":"Mass spectrometry of p53 complexes; in vitro DUB assay; catalytic-dead mutant destabilizing p53","pmids":["11923872"],"confidence":"High","gaps":["Whether HAUSP also deubiquitinates MDM2 (creating a regulatory triangle) not addressed","Signals that regulate HAUSP activity unknown"]},{"year":2004,"claim":"Two breakthroughs expanded p53's functional repertoire and therapeutic tractability: reconstitution of transcription-independent apoptosis via direct p53–Bax interaction at mitochondria, and development of Nutlin small molecules that displace p53 from MDM2 to reactivate the pathway in wild-type TP53 tumors.","evidence":"Purified p53–Bax mitochondrial permeabilization assay; Nutlin–MDM2 co-crystal structure with xenograft tumor inhibition","pmids":["14963330","14704432"],"confidence":"High","gaps":["Relative contribution of cytosolic versus nuclear p53 to apoptosis in vivo not quantified","Nutlin efficacy in patients not yet demonstrated"]},{"year":2005,"claim":"Discovery of alternative p53 isoforms (p53β, Δ133p53) from an internal promoter revealed that the TP53 locus encodes functionally opposing proteins, with Δ133p53 acting as a dominant-negative inhibitor of full-length p53.","evidence":"RT-PCR; reporter assays; antisense inhibition showing dominant-negative effects","pmids":["16131611"],"confidence":"High","gaps":["Relative abundance and tissue specificity of isoforms in normal tissues not systematically mapped","Whether isoforms form mixed tetramers with full-length p53 not structurally resolved"]},{"year":2007,"claim":"Identification of miR-34a as a direct p53 transcriptional target that mediates widespread gene repression extended the p53 network into non-coding RNA-based gene regulation.","evidence":"ChIP showing p53 binding at miR-34a promoter; miR-34a overexpression with expression arrays and apoptosis readout","pmids":["17540599"],"confidence":"High","gaps":["Whether miR-34a is required for p53-mediated tumor suppression in vivo not tested genetically","Other p53-regulated miRNAs not systematically catalogued"]},{"year":2010,"claim":"USP10 was identified as a cytoplasmic deubiquitinase that reverses MDM2-mediated p53 ubiquitination and translocates to the nucleus upon ATM-dependent phosphorylation, adding a spatially regulated layer to p53 stabilization after DNA damage.","evidence":"In vitro DUB assay; ATM phosphorylation site mapping; subcellular fractionation; USP10 knockdown","pmids":["20096447"],"confidence":"High","gaps":["Whether USP10 and HAUSP act redundantly or on distinct p53 pools not determined","Structural basis of USP10–p53 interaction unknown"]},{"year":2010,"claim":"Discovery that p53 induces the long non-coding RNA lincRNA-p21, which recruits hnRNP-K to repress hundreds of genes, established a mechanism for p53-mediated transcriptional repression through lncRNA scaffolding.","evidence":"RNA-seq; RNA immunoprecipitation for hnRNP-K; lincRNA-p21 knockdown with gene expression profiling","pmids":["20673990"],"confidence":"High","gaps":["Whether lincRNA-p21 acts in cis or trans genome-wide not resolved","Contribution of lincRNA-p21 to tumor suppression in vivo not tested"]},{"year":2015,"claim":"Demonstration that p53 represses SLC7A11 to promote ferroptosis — and that an acetylation-defective p53 mutant retaining this activity still suppresses tumors — identified ferroptosis as a p53-dependent tumor-suppressive program separable from canonical cell-cycle arrest and apoptosis.","evidence":"ChIP; p53 3KR acetylation-defective mutant; SLC7A11 overexpression rescue; xenograft assays; ferroptosis death assays","pmids":["25799988"],"confidence":"High","gaps":["Whether ferroptosis is the critical tumor-suppressive output in specific tissue contexts not defined","Mechanism of SLC7A11 transcriptional repression (co-repressor identity) not determined"]},{"year":2016,"claim":"Studies of the African-specific p53 S47 variant revealed selective loss of metabolic target gene induction and ferroptosis, while combined TP53/RB1 loss was shown to enable lineage plasticity in prostate cancer through SOX2, expanding p53's tumor-suppressive roles to metabolic regulation and cell fate determination.","evidence":"S47 knockin mice with spontaneous tumors and ferroptosis assays; TP53/RB1 knockout prostate cancer models with SOX2 analysis","pmids":["27034505","28059768"],"confidence":"High","gaps":["Whether S47 variant affects immune-mediated tumor suppression not tested","Mechanistic basis for p53/Rb cooperation in lineage plasticity not molecularly defined"]},{"year":2019,"claim":"Identification of β-hydroxybutyrylation of p53 by CBP at Lys120/319/370 during ketosis, competing with acetylation and attenuating transcriptional activity, revealed a metabolite-driven mechanism linking fasting to p53 dampening.","evidence":"Mass spectrometry; CBP in vitro Kbhb assay; BHB-treated cells and fasted mouse thymus; p53 target gene expression","pmids":["30858356"],"confidence":"Medium","gaps":["Physiological significance of Kbhb versus acetylation competition not quantified at endogenous levels","Whether Kbhb has independent signaling functions beyond blocking acetylation unknown","Independent replication of Kbhb modification pending"]},{"year":2021,"claim":"Discovery that ZDHHC1-mediated palmitoylation at three cysteines in the p53 core domain is required for nuclear translocation introduced lipid modification as a regulator of p53 localization, with a reciprocal epigenetic feedback loop silencing ZDHHC1 through p53-recruited DNMT3A.","evidence":"Acyl-RAC assay; cysteine mutagenesis; nuclear fractionation; ChIP for DNMT3A at ZDHHC1 promoter","pmids":["34282274"],"confidence":"Medium","gaps":["Whether palmitoylation is constitutive or signal-regulated not defined","Impact on DNA-binding domain structure (palmitoylated cysteines overlap with zinc-coordinating region) not assessed","Independent replication of palmitoylation requirement for nuclear entry pending"]},{"year":2023,"claim":"Structural and functional characterization of the African-centric Y107H variant revealed selective loss of PADI4 transactivation and an immune-dependent tumor-suppressive axis, uncovering a p53–PADI4–immune surveillance pathway relevant to immunotherapy response.","evidence":"NMR and crystal structure of Y107H; Y107H knockin mouse tumor models; PADI4 KO mice; immune depletion","pmids":["37140445"],"confidence":"High","gaps":["How PADI4-mediated citrullination connects to immune recognition not molecularly defined","Whether the p53-PADI4 signature generalizes beyond the cohorts tested unknown"]},{"year":null,"claim":"Major unresolved questions include: how the relative contributions of p53's diverse outputs (arrest, apoptosis, senescence, ferroptosis, immune surveillance) are determined in a tissue- and context-specific manner; the full structural basis of tetrameric p53 on chromatin with co-regulators; and how the many post-translational modifications are integrated combinatorially to specify target gene selection.","evidence":"","pmids":[],"confidence":"High","gaps":["Full-length p53 tetramer structure on DNA with cofactors not resolved","Combinatorial PTM code for target gene selectivity not decoded","Tissue-specific determinants of p53 output choice not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,8,16,23,30,32]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[8,9,15,16,18,23,25,30,32]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17,24,29]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[14,17]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[14]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,14,23,33]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[9,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,10,17,20]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[7,10,17]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[16,18,23,30,32]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2,3,4,25,33]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[9,23,27]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[32]}],"complexes":["p53 homotetramer"],"partners":["MDM2","HAUSP","USP10","SIRT1","EP300","BAX","TP53BP2","UBE3A"],"other_free_text":[]},"mechanistic_narrative":"p53 is a tetrameric transcription factor and master tumor suppressor that integrates diverse stress signals to execute cell cycle arrest, apoptosis, senescence, and ferroptosis. Its core DNA-binding domain, a zinc-stabilized β-sandwich scaffold, recognizes specific response elements in target genes including p21, PUMA, miR-34a, SLC7A11, and MKP1, while also functioning in a transcription-independent manner by directly activating the proapoptotic protein Bax at mitochondria [PMID:8023157, PMID:14963330, PMID:25799988, PMID:17540599]. p53 stability and activity are governed by an elaborate network of post-translational modifications: MDM2-mediated ubiquitination targets p53 for proteasomal degradation, counteracted by deubiquitinases HAUSP and USP10; DNA-damage-induced phosphorylation at Ser15 by ATM and DNA-PK disrupts MDM2 binding; and p300/CBP-mediated acetylation at C-terminal lysines enhances DNA binding, while SIRT1-mediated deacetylation attenuates transcriptional output [PMID:9450543, PMID:11923872, PMID:20096447, PMID:9733515, PMID:9288740, PMID:11672523]. TP53 somatic mutations cluster in the conserved DNA-contact and structural residues of the core domain and are found across virtually all human tumor types; viral inactivation occurs through the HPV E6–E6AP ubiquitin ligase complex, while MDM2 gene amplification provides a non-mutational route to p53 inactivation, and alternative p53 isoforms such as Δ133p53 can dominantly antagonize full-length p53 function [PMID:1905840, PMID:2157286, PMID:1614537, PMID:16131611]."},"prefetch_data":{"uniprot":{"accession":"P04637","full_name":"Cellular tumor antigen p53","aliases":["Antigen NY-CO-13","Phosphoprotein p53","Tumor suppressor p53"],"length_aa":393,"mass_kda":43.7,"function":"Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:38653238, PubMed:9840937). Negatively regulates cell division by controlling expression of a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P04637/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TP53","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2},{"gene":"POLR3B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TP53","total_profiled":1310},"omim":[{"mim_id":"621522","title":"SCAFFOLDING CK1-ANCHORING PROTEIN F; SACK1F","url":"https://www.omim.org/entry/621522"},{"mim_id":"621515","title":"UBIQUITIN-CONJUGATING ENZYME E2 D4; UBE2D4","url":"https://www.omim.org/entry/621515"},{"mim_id":"621451","title":"SMALL NUCLEOLAR RNA HOST GENE 12; SNHG12","url":"https://www.omim.org/entry/621451"},{"mim_id":"621436","title":"MICROCEPHALY, PROGRESSIVE, WITH SIMPLIFIED GYRAL PATTERN AND CEREBELLAR HYPOPLASIA; MGCH","url":"https://www.omim.org/entry/621436"},{"mim_id":"621430","title":"FIGNL1-INTERACTING REGULATOR OF RECOMBINATION AND MITOSIS; FIRRM","url":"https://www.omim.org/entry/621430"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TP53"},"hgnc":{"alias_symbol":["p53","LFS1"],"prev_symbol":[]},"alphafold":{"accession":"P04637","domains":[{"cath_id":"2.60.40.720","chopping":"109-287","consensus_level":"high","plddt":95.1398,"start":109,"end":287}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P04637","model_url":"https://alphafold.ebi.ac.uk/files/AF-P04637-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P04637-F1-predicted_aligned_error_v6.png","plddt_mean":75.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TP53","jax_strain_url":"https://www.jax.org/strain/search?query=TP53"},"sequence":{"accession":"P04637","fasta_url":"https://rest.uniprot.org/uniprotkb/P04637.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P04637/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P04637"}},"corpus_meta":[{"pmid":"28059768","id":"PMC_28059768","title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28059768","citation_count":878,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11923872","id":"PMC_11923872","title":"Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11923872","citation_count":861,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16131611","id":"PMC_16131611","title":"p53 isoforms can regulate p53 transcriptional activity.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16131611","citation_count":676,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27328919","id":"PMC_27328919","title":"TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.","date":"2016","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/27328919","citation_count":604,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20096447","id":"PMC_20096447","title":"USP10 regulates p53 localization and stability by deubiquitinating p53.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20096447","citation_count":510,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29099487","id":"PMC_29099487","title":"Why are there hotspot mutations in the TP53 gene in human cancers?","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29099487","citation_count":467,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27840695","id":"PMC_27840695","title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.","date":"2016","source":"The journal of pathology. Clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/27840695","citation_count":326,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27034505","id":"PMC_27034505","title":"An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27034505","citation_count":305,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33649166","id":"PMC_33649166","title":"Targeting a neoantigen derived from a common TP53 mutation.","date":"2021","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33649166","citation_count":285,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11511362","id":"PMC_11511362","title":"p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11511362","citation_count":283,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17719538","id":"PMC_17719538","title":"Living with p53, dying of p53.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17719538","citation_count":254,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26024390","id":"PMC_26024390","title":"TP53: an oncogene in disguise.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26024390","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31829441","id":"PMC_31829441","title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.","date":"2020","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31829441","citation_count":244,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20300207","id":"PMC_20300207","title":"Clinical outcomes and correlates of TP53 mutations and cancer.","date":"2010","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20300207","citation_count":233,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26563132","id":"PMC_26563132","title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26563132","citation_count":231,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27141080","id":"PMC_27141080","title":"Tumor-Suppressor Functions of the TP53 Pathway.","date":"2016","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27141080","citation_count":226,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19250907","id":"PMC_19250907","title":"Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage.","date":"2009","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19250907","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26982726","id":"PMC_26982726","title":"Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26982726","citation_count":212,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21837677","id":"PMC_21837677","title":"Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database.","date":"2011","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21837677","citation_count":191,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12619104","id":"PMC_12619104","title":"TP53 family members and human cancers.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619104","citation_count":189,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12619106","id":"PMC_12619106","title":"TP53 and liver carcinogenesis.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619106","citation_count":186,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8718514","id":"PMC_8718514","title":"Germline mutations in the TP53 gene.","date":"1995","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/8718514","citation_count":170,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26882543","id":"PMC_26882543","title":"NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/26882543","citation_count":161,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32203095","id":"PMC_32203095","title":"Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.","date":"2020","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/32203095","citation_count":157,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11900880","id":"PMC_11900880","title":"TP53: a key gene in human cancer.","date":"2002","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/11900880","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12619117","id":"PMC_12619117","title":"The role of TP53 in Cervical carcinogenesis.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619117","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27821766","id":"PMC_27821766","title":"Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27821766","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30858356","id":"PMC_30858356","title":"p53 β-hydroxybutyrylation attenuates p53 activity.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30858356","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34878954","id":"PMC_34878954","title":"Autophagy inhibition mediated by MCOLN1/TRPML1 suppresses cancer metastasis via regulating a ROS-driven TP53/p53 pathway.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34878954","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12619114","id":"PMC_12619114","title":"TP53 and ovarian cancer.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619114","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35332311","id":"PMC_35332311","title":"Should mutant TP53 be targeted for cancer therapy?","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35332311","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19918835","id":"PMC_19918835","title":"Massively regulated genes: the example of TP53.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19918835","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25896519","id":"PMC_25896519","title":"Germline TP53 variants and susceptibility to osteosarcoma.","date":"2015","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/25896519","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30907951","id":"PMC_30907951","title":"Understanding p53 functions through p53 antibodies.","date":"2019","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30907951","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24634504","id":"PMC_24634504","title":"Rare variants in TP53 and susceptibility to neuroblastoma.","date":"2014","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/24634504","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9338102","id":"PMC_9338102","title":"Maintaining genetic stability through TP53 mediated checkpoint control.","date":"1997","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/9338102","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27885271","id":"PMC_27885271","title":"p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27885271","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36766853","id":"PMC_36766853","title":"The Role of TP53 in Adaptation and Evolution.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36766853","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12101227","id":"PMC_12101227","title":"E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12101227","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11764090","id":"PMC_11764090","title":"Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas.","date":"2001","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11764090","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30255938","id":"PMC_30255938","title":"Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30255938","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11375905","id":"PMC_11375905","title":"Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation.","date":"2001","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11375905","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27449973","id":"PMC_27449973","title":"Clinical Outcomes of TP53 Mutations in Cancers.","date":"2016","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27449973","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35658479","id":"PMC_35658479","title":"TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.","date":"2022","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35658479","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7905277","id":"PMC_7905277","title":"TP53 allele loss, mutations and expression in malignant melanoma.","date":"1994","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7905277","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11454518","id":"PMC_11454518","title":"Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.","date":"2001","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11454518","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12619110","id":"PMC_12619110","title":"TP53 and head and neck neoplasms.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619110","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9546285","id":"PMC_9546285","title":"Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.","date":"1998","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/9546285","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30687640","id":"PMC_30687640","title":"Deregulation and Targeting of TP53 Pathway in Multiple Myeloma.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30687640","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17188467","id":"PMC_17188467","title":"The p53 network: p53 and its downstream genes.","date":"2006","source":"Colloids and surfaces. B, Biointerfaces","url":"https://pubmed.ncbi.nlm.nih.gov/17188467","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24395704","id":"PMC_24395704","title":"Mutant TP53 posttranslational modifications: challenges and opportunities.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24395704","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27630122","id":"PMC_27630122","title":"TP53 drives invasion through expression of its Δ133p53β variant.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27630122","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38666907","id":"PMC_38666907","title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.","date":"2024","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38666907","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34503094","id":"PMC_34503094","title":"TP53 in Biology and Treatment of Osteosarcoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34503094","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32630614","id":"PMC_32630614","title":"Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32630614","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27582538","id":"PMC_27582538","title":"TP53 mutation hits energy metabolism and increases glycolysis in breast cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27582538","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25471832","id":"PMC_25471832","title":"USP11 regulates p53 stability by deubiquitinating p53.","date":"2014","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/25471832","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34389799","id":"PMC_34389799","title":"Spontaneous and inherited TP53 genetic alterations.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34389799","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30993195","id":"PMC_30993195","title":"Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.","date":"2019","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30993195","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30466751","id":"PMC_30466751","title":"Patterns of mutations in TP53 mutated AML.","date":"2018","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/30466751","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20504346","id":"PMC_20504346","title":"Expression signatures of TP53 mutations in serous ovarian cancers.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20504346","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27003724","id":"PMC_27003724","title":"TP53 mutation, mitochondria and cancer.","date":"2016","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/27003724","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32075247","id":"PMC_32075247","title":"p53's Extended Reach: The Mutant p53 Secretome.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32075247","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24143256","id":"PMC_24143256","title":"OTUD5 regulates p53 stability by deubiquitinating p53.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24143256","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31776983","id":"PMC_31776983","title":"TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy.","date":"2019","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/31776983","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32703491","id":"PMC_32703491","title":"Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer.","date":"2020","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/32703491","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8013000","id":"PMC_8013000","title":"The role of TP53 in breast cancer development.","date":"1993","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/8013000","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34282274","id":"PMC_34282274","title":"Cancer cells escape p53's tumor suppression through ablation of ZDHHC1-mediated p53 palmitoylation.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34282274","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21804386","id":"PMC_21804386","title":"Role of TP53 mutations in vulvar carcinomas.","date":"2011","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/21804386","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17369843","id":"PMC_17369843","title":"RB1 and TP53 pathways in radiation-induced sarcomas.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17369843","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34017087","id":"PMC_34017087","title":"TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34017087","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23165797","id":"PMC_23165797","title":"Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.","date":"2012","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23165797","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25847421","id":"PMC_25847421","title":"TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts.","date":"2015","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/25847421","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14745430","id":"PMC_14745430","title":"Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.","date":"2004","source":"The hematology journal : the official journal of the European Haematology Association","url":"https://pubmed.ncbi.nlm.nih.gov/14745430","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36471402","id":"PMC_36471402","title":"p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.","date":"2022","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36471402","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24630986","id":"PMC_24630986","title":"Plk1-targeted therapies in TP53- or RAS-mutated cancer.","date":"2014","source":"Mutation research. Reviews in mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/24630986","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23029043","id":"PMC_23029043","title":"The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029043","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29307398","id":"PMC_29307398","title":"p53 and reproduction.","date":"2018","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/29307398","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39443700","id":"PMC_39443700","title":"TP53: the unluckiest of genes?","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/39443700","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15922892","id":"PMC_15922892","title":"Mutation and methylation analysis of TP53 in adrenal carcinogenesis.","date":"2005","source":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15922892","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32238876","id":"PMC_32238876","title":"p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns.","date":"2020","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/32238876","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32724153","id":"PMC_32724153","title":"Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.","date":"2020","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/32724153","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33514515","id":"PMC_33514515","title":"Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33514515","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31346036","id":"PMC_31346036","title":"Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31346036","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33555293","id":"PMC_33555293","title":"Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer.","date":"2021","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/33555293","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27813088","id":"PMC_27813088","title":"Nutlin-3a selects for cells harbouring TP53 mutations.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27813088","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29572430","id":"PMC_29572430","title":"Rlip depletion prevents spontaneous neoplasia in TP53 null mice.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29572430","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31968253","id":"PMC_31968253","title":"A Mouse Homolog of a Human TP53 Germline Mutation Reveals a Lipolytic Activity of p53.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31968253","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16827804","id":"PMC_16827804","title":"Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis.","date":"2006","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/16827804","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37140445","id":"PMC_37140445","title":"An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression.","date":"2023","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37140445","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29769598","id":"PMC_29769598","title":"Germline mutation in the TP53 gene in uveal melanoma.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29769598","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20025891","id":"PMC_20025891","title":"Profile of TP53 gene mutations in sinonasal cancer.","date":"2009","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/20025891","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34404905","id":"PMC_34404905","title":"Immunohistochemical staining patterns of p53 predict the mutational status of TP53 in oral epithelial dysplasia.","date":"2021","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/34404905","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36485102","id":"PMC_36485102","title":"Transplant for TP53-mutated MDS and AML: because we can or because we should?","date":"2022","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/36485102","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10718212","id":"PMC_10718212","title":"TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.","date":"2000","source":"Diagnostic molecular pathology : the American journal of surgical pathology, part B","url":"https://pubmed.ncbi.nlm.nih.gov/10718212","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20023260","id":"PMC_20023260","title":"Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.","date":"2010","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20023260","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15611668","id":"PMC_15611668","title":"p53 Transactivates the phosphatase MKP1 through both intronic and exonic p53 responsive elements.","date":"2004","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15611668","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32089220","id":"PMC_32089220","title":"Targeting TP53 Mutations in Myelodysplastic Syndromes.","date":"2019","source":"Hematology/oncology clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/32089220","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24489863","id":"PMC_24489863","title":"BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24489863","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24736457","id":"PMC_24736457","title":"Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.","date":"2014","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24736457","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1905840","id":"PMC_1905840","title":"p53 mutations in human cancers.","date":"1991","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1905840","citation_count":7714,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9054499","id":"PMC_9054499","title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9054499","citation_count":4238,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14704432","id":"PMC_14704432","title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14704432","citation_count":3869,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1978757","id":"PMC_1978757","title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1978757","citation_count":3180,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2531845","id":"PMC_2531845","title":"Mutations in the p53 gene occur in diverse human tumour types.","date":"1989","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2531845","citation_count":2953,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14976264","id":"PMC_14976264","title":"Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14976264","citation_count":2764,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25799988","id":"PMC_25799988","title":"Ferroptosis as a p53-mediated activity during tumour suppression.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25799988","citation_count":2746,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19410540","id":"PMC_19410540","title":"Blinded by the Light: The Growing Complexity of p53.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19410540","citation_count":2583,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26061751","id":"PMC_26061751","title":"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.","date":"2015","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26061751","citation_count":2459,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2157286","id":"PMC_2157286","title":"Association of human papillomavirus types 16 and 18 E6 proteins with p53.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2157286","citation_count":2366,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11672523","id":"PMC_11672523","title":"hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.","date":"2001","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11672523","citation_count":2263,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9288740","id":"PMC_9288740","title":"Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9288740","citation_count":2223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8023157","id":"PMC_8023157","title":"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8023157","citation_count":2211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8221889","id":"PMC_8221889","title":"The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8221889","citation_count":2052,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23788249","id":"PMC_23788249","title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.","date":"2013","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23788249","citation_count":1945,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1614537","id":"PMC_1614537","title":"Amplification of a gene encoding a p53-associated protein in human sarcomas.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1614537","citation_count":1933,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8875929","id":"PMC_8875929","title":"Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8875929","citation_count":1841,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9363941","id":"PMC_9363941","title":"DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9363941","citation_count":1783,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20177397","id":"PMC_20177397","title":"Genomic instability--an evolving hallmark of cancer.","date":"2010","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20177397","citation_count":1769,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20673990","id":"PMC_20673990","title":"A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20673990","citation_count":1728,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9733515","id":"PMC_9733515","title":"Activation of the ATM kinase by ionizing radiation and phosphorylation of p53.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9733515","citation_count":1694,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14963330","id":"PMC_14963330","title":"Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14963330","citation_count":1679,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9450543","id":"PMC_9450543","title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9450543","citation_count":1655,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17540599","id":"PMC_17540599","title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17540599","citation_count":1638,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20182602","id":"PMC_20182602","title":"TP53 mutations in human cancers: origins, consequences, and clinical use.","date":"2010","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20182602","citation_count":1601,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15205477","id":"PMC_15205477","title":"Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15205477","citation_count":1596,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28886379","id":"PMC_28886379","title":"Putting p53 in Context.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28886379","citation_count":1548,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45685,"output_tokens":5487,"usd":0.10968},"stage2":{"model":"claude-opus-4-6","input_tokens":9088,"output_tokens":4477,"usd":0.236047},"total_usd":0.777805,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":56557,"output_tokens":8277,"usd":0.146913},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12387,"output_tokens":5127,"usd":0.285165}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"HAUSP (herpesvirus-associated ubiquitin-specific protease) directly deubiquitinates p53 both in vitro and in vivo, stabilizing it even in the presence of excess Mdm2; a catalytically inactive HAUSP mutant increases p53 ubiquitination and destabilizes p53.\",\n      \"method\": \"Mass spectrometry of affinity-purified p53-associated factors, in vitro deubiquitination assay, co-immunoprecipitation, catalytically inactive point mutant analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic reconstitution plus mutagenesis plus in vivo validation in a single highly cited study\",\n      \"pmids\": [\"11923872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"USP10, a cytoplasmic ubiquitin-specific protease, deubiquitinates p53 and reverses Mdm2-induced p53 nuclear export and degradation; after DNA damage, ATM phosphorylates USP10 at Thr42 and Ser337, stabilizing USP10 and causing a fraction to translocate to the nucleus to activate p53.\",\n      \"method\": \"Co-immunoprecipitation, in vitro deubiquitination assay, subcellular fractionation/localization, ATM kinase assay, USP10 knockdown with phenotypic readout\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including in vitro assay, identified writer (ATM), localization with functional consequence\",\n      \"pmids\": [\"20096447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The human p53 gene contains an alternative internal promoter in intron 3 that produces isoforms including p53β and Δ133p53; p53β can enhance p53 target gene expression in a promoter-dependent manner, while Δ133p53 acts as a dominant-negative toward full-length p53 and inhibits p53-mediated apoptosis.\",\n      \"method\": \"Identification of alternative promoter by sequencing, reporter gene assays, overexpression and knockdown with apoptosis readout, gene expression analysis in normal and tumor tissues\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays demonstrating distinct activities of isoforms, replicated in normal human tissue and breast tumors\",\n      \"pmids\": [\"16131611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Wrap53, a natural antisense transcript of p53, stabilizes endogenous p53 mRNA by targeting its 5' UTR via RNA–RNA interaction; Wrap53 knockdown decreases p53 mRNA and suppresses p53 protein induction upon DNA damage, while overexpression increases p53 levels and sensitizes cells to p53-dependent apoptosis.\",\n      \"method\": \"siRNA knockdown, overexpression, blocking of Wrap53/p53 RNA hybrids, quantitative RT-PCR, apoptosis assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches including RNA hybrid blockade, knockdown, and overexpression with mechanistic and functional readouts\",\n      \"pmids\": [\"19250907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p53DINP1 (p53-dependent damage-inducible nuclear protein 1) is a p53-inducible gene whose product co-factors with a Ser46 kinase complex to phosphorylate p53 at Ser46; antisense inhibition of p53DINP1 blocks Ser46 phosphorylation, p53AIP1 induction, and DNA double-strand break-induced apoptosis, while overexpression synergistically enhances these events.\",\n      \"method\": \"Differential display cloning, antisense oligonucleotide knockdown, overexpression, in vitro kinase assay on p53 Ser46, apoptosis readout\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay identifying complex phosphorylating p53-Ser46, corroborated by loss-of-function and gain-of-function experiments\",\n      \"pmids\": [\"11511362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NAT10 acetylates p53 at K120 and promotes Mdm2 degradation via its intrinsic E3 ligase activity; after DNA damage, NAT10 translocates from nucleolus to nucleoplasm and activates p53-mediated cell cycle arrest and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro acetylation assay, E3 ligase assay, subcellular fractionation, knockdown with functional readouts\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic assay for both acetyltransferase and E3 ligase activities, plus localization with functional consequence\",\n      \"pmids\": [\"26882543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"β-hydroxybutyrate (BHB) induces β-hydroxybutyrylation (Kbhb) of p53 at lysines K120, K319, and K370, catalyzed by CBP; p53 Kbhb reduces p53 acetylation, decreases expression of p21 and PUMA, and attenuates p53-dependent growth arrest and apoptosis.\",\n      \"method\": \"Mass spectrometry identification of modification sites, in vitro acylation assay with CBP, cell treatment with BHB, gene expression analysis, apoptosis and growth arrest assays, mouse thymus tissue analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — identified writer (CBP), mapped sites, functional consequence shown, but single lab study\",\n      \"pmids\": [\"30858356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OTUD5 is a deubiquitinase that directly interacts with p53, deubiquitinates it, and is required for rapid activation of p53-dependent transcription and apoptosis in response to DNA damage.\",\n      \"method\": \"Co-immunoprecipitation, in vitro deubiquitination assay, knockdown with transcriptional and apoptosis readouts\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro enzymatic assay plus loss-of-function with functional readouts, single lab\",\n      \"pmids\": [\"24143256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"USP11, an ubiquitin-specific protease, forms specific complexes with p53, deubiquitinates it, stabilizes p53, and is required for p53 induction in response to DNA damage stress.\",\n      \"method\": \"Co-immunoprecipitation, in vitro deubiquitination assay, knockdown with p53 stability readout\",\n      \"journal\": \"Journal of Zhejiang University. Science. B\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, limited orthogonal validation beyond pull-down and stability assay\",\n      \"pmids\": [\"25471832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"E2F1 induces phosphorylation of p53 at multiple N- and C-terminal sites in a p19ARF-independent manner, similar to DNA-damage-induced modifications; this phosphorylation is required for E2F1-mediated apoptosis and is blocked by caffeine (a PI3K-related kinase inhibitor), placing DNA-damage kinase signaling downstream of E2F1 and upstream of p53-dependent apoptosis.\",\n      \"method\": \"Genetic epistasis (p19ARF-null MEFs), phosphorylation site mutant p53, pharmacological inhibition with caffeine, apoptosis readout\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis with null cells plus p53 phospho-mutant plus pharmacological blockade, multiple orthogonal approaches\",\n      \"pmids\": [\"12101227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"p53 transactivates the MAPK phosphatase MKP1 through two distinct p53 responsive elements: one intronic and one exonic; both elements can independently confer p53 responsiveness, and both are required for full activation, as demonstrated by chromatin immunoprecipitation and gel-shift assays.\",\n      \"method\": \"Reporter gene assays, gel-shift (EMSA), chromatin immunoprecipitation (ChIP), site-directed mutagenesis of responsive elements\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro and in vivo DNA binding demonstrated by EMSA and ChIP, with mutagenesis confirming functional elements\",\n      \"pmids\": [\"15611668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FBW7α, the substrate-recognition subunit of the SCF E3 ligase complex, ubiquitinates p53 via Lys-48 linkages at Lys-132, requiring prior phosphorylation of p53 at Ser-33 (by GSK3β) and Ser-37 (by DNA-PK) to create a phosphodegron; this FBW7α-mediated degradation occurs during and immediately after DNA double-strand breaks.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, mutagenesis of phosphorylation sites and ubiquitination site, kinase inhibitor experiments, half-life measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of ubiquitination, identified writers (GSK3β, DNA-PK), mapped sites by mutagenesis\",\n      \"pmids\": [\"31346036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Deoxycholic acid (DCA) suppresses p53 protein accumulation through proteasome-mediated degradation dependent on nuclear export via CRM1 and ERK signaling; lactacystin (proteasome inhibitor) and leptomycin B (CRM1 inhibitor) both block DCA-induced p53 suppression.\",\n      \"method\": \"Pharmacological inhibition with lactacystin and leptomycin B, ERK pathway blockade, protein stability assay, transcriptional activity assay\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological probes with orthogonal readouts, single lab but converging mechanistic evidence\",\n      \"pmids\": [\"11375905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZDHHC1, an S-palmitoyltransferase, palmitoylates p53 at Cys135, Cys176, and Cys275; this palmitoylation is required for nuclear translocation of p53. In turn, p53 recruits DNMT3A to the ZDHHC1 promoter, causing its hypermethylation and silencing, forming an epigenetic feedback loop.\",\n      \"method\": \"Identification of palmitoylation sites by mass spectrometry, mutagenesis, nuclear/cytoplasmic fractionation, co-immunoprecipitation of DNMT3A with p53, ChIP at ZDHHC1 promoter, methylation analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mapped modification sites, identified writer (ZDHHC1), showed functional consequence (nuclear translocation), single lab\",\n      \"pmids\": [\"34282274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The p53 isoform Δ133p53β (derived from the alternative intron 3 promoter of TP53) promotes cancer cell invasion and epithelial-mesenchymal transition (EMT) in breast and colon cancer cell lines regardless of full-length TP53 mutation status; depletion of endogenous Δ133p53β prevents invasiveness without affecting full-length mutant p53.\",\n      \"method\": \"siRNA knockdown of specific isoform, overexpression, EMT marker analysis, invasion assays, clinical sample correlation\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific knockdown with defined cellular phenotype across multiple cell lines, mechanistic link to EMT\",\n      \"pmids\": [\"27630122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A mouse model of the human TP53 R181C germline mutation (p53 R178C knockin) reveals that p53 binds and transactivates the Beta-3-Adrenergic Receptor (ADRB3) gene, promoting lipolysis in adipose tissue; ChIP-seq confirms direct p53 occupancy at the ADRB3 locus.\",\n      \"method\": \"Knockin mouse model, ChIP-seq, gene expression analysis, metabolic phenotyping\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq demonstrates direct p53 binding to ADRB3, in vivo phenotype in knockin model, single lab\",\n      \"pmids\": [\"31968253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The p53-46F mutant (Ser46→Phe substitution) acts as a 'super p53' with enhanced Ser15 phosphorylation, decreased p21/WAF1 expression, and increased transactivation of pro-apoptotic targets (Noxa, p53AIP1, p53RFP), resulting in more potent induction of p53-dependent apoptosis than wild-type p53.\",\n      \"method\": \"Adenovirus-mediated gene transduction, apoptosis assays, Western blotting for phosphorylation, luciferase reporter assays for target gene transactivation, in vivo xenograft\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structure-function mutagenesis with multiple orthogonal readouts, functional consequence in vitro and in vivo\",\n      \"pmids\": [\"16827804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TP53TG1, a p53-induced lncRNA, binds to the multifunctional DNA/RNA-binding protein YBX1 to prevent its nuclear localization, thereby blocking YBX1-mediated activation of oncogenes; epigenetic silencing of TP53TG1 releases YBX1 to the nucleus and creates chemoresistance.\",\n      \"method\": \"RNA immunoprecipitation, subcellular localization (fractionation and imaging), in vitro and in vivo tumor suppression assays, promoter methylation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-protein interaction demonstrated, subcellular localization consequence linked to oncogene activation, in vivo validation\",\n      \"pmids\": [\"27821766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The African-specific TP53 germline variant Y107H is structurally similar to wild-type p53 but selectively impairs transactivation of a small subset of targets including PADI4 (a deiminase converting arginine to citrulline); PADI4 is itself tumor suppressive and requires an intact immune system for tumor suppression; Y107H mice develop spontaneous cancers.\",\n      \"method\": \"NMR and crystal structure of Y107H, transcriptional profiling, tumor colony formation assays, knockin mouse model, PADI4 functional assays\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus NMR, transactivation assays, in vivo mouse model with multiple cancer endpoints\",\n      \"pmids\": [\"37140445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The African-specific TP53 S47 variant (codon 47, Pro→Ser) shows impaired transactivation of metabolic target genes Gls2 and Sco2, is markedly resistant to ferroptotic cell death, and is modestly defective in cisplatin-induced apoptosis; S47 mice in homo- or heterozygous form develop spontaneous cancers.\",\n      \"method\": \"Human cell lines and mouse knockin model, gene expression analysis, apoptosis assays, ferroptosis assays, tumorigenesis monitoring\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays in both human cells and mouse model, identifies specific target genes impaired\",\n      \"pmids\": [\"27034505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-3151 directly binds to the 3' UTR of TP53 mRNA, reducing TP53 abundance; overexpression of miR-3151 reduces p53 protein, decreases apoptosis and chemosensitivity, and increases leukemogenesis in mice, while miR-3151 knockdown increases caspase activity.\",\n      \"method\": \"3' UTR luciferase reporter assay, Western blot for TP53 protein, overexpression and knockdown with apoptosis/caspase readouts, mouse leukemogenesis model\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3' UTR binding demonstrated, in vivo leukemogenesis model, multiple functional readouts\",\n      \"pmids\": [\"24736457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HPV E6 protein, in complex with E6AP (an E3 ubiquitin ligase), binds p53 and catalyzes its multi-ubiquitination and proteasomal degradation; this activity is exclusive to high-risk HPV E6 proteins, as low-risk E6 can bind but not degrade p53.\",\n      \"method\": \"Biochemical interaction studies, ubiquitination assays, functional degradation assays comparing high- and low-risk HPV E6\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established by biochemical assays distinguishing high- vs low-risk HPV E6; foundational work cited and described in review context (PMID 12619117)\",\n      \"pmids\": [\"12619117\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TP53 encodes p53, a transcription factor and tumor suppressor that is maintained at low levels by Mdm2-mediated ubiquitination and proteasomal degradation, and is stabilized by multiple deubiquitinases (HAUSP/USP7, USP10, USP11, OTUD5) and post-translational modifications including phosphorylation (by ATM, GSK3β, DNA-PK at multiple sites), acetylation (by CBP at K120, NAT10 at K120), β-hydroxybutyrylation (by CBP at K120/K319/K370, attenuating activity), and palmitoylation (by ZDHHC1 at C135/C176/C275, required for nuclear import); p53 acts as a sequence-specific transcriptional activator of cell cycle arrest genes (e.g., p21/MKP1) and pro-apoptotic genes (e.g., p53AIP1, Noxa, PUMA, PADI4), with Ser46 phosphorylation gated by p53DINP1 determining apoptotic output, while distinct isoforms (Δ133p53β) promote invasion and EMT independently of full-length p53 status, and its mRNA is post-transcriptionally regulated by the natural antisense transcript Wrap53 and by miR-3151 targeting its 3' UTR.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"p53 mutations occur in diverse human tumor types and are concentrated in four highly conserved regions of the DNA-binding domain, with mutational spectra that differ by tumor type and correlate with carcinogen exposure (e.g., G:C to T:A transversions in lung/liver cancers, C-to-T transitions at CpG hotspots in colon/brain tumors, codon 249 hotspot in aflatoxin-associated liver cancer).\",\n      \"method\": \"Direct DNA sequencing across multiple tumor types\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — landmark multi-tumor sequencing study, independently replicated across labs; foundational paper with >7000 citations\",\n      \"pmids\": [\"1905840\", \"2531845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The crystal structure of the p53 core domain (residues 102–292) bound to DNA revealed a β-sandwich scaffold supporting two large loops (held together by a zinc atom) and a loop-sheet-helix motif that forms the DNA-binding surface; tumor-derived mutations cluster in these conserved structural elements, explaining their loss of DNA-binding activity.\",\n      \"method\": \"X-ray crystallography at 2.2 Å resolution; structural analysis of tumor mutant positions\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with direct mechanistic interpretation of mutant residues; >2200 citations\",\n      \"pmids\": [\"8023157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"HPV-16 and HPV-18 E6 oncoproteins physically associate with the p53 tumor suppressor protein; this interaction correlates with the transforming activity of different HPV types, providing a mechanism for viral inactivation of p53.\",\n      \"method\": \"Co-immunoprecipitation / in vitro binding assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated in multiple assays, replicated; >2300 citations\",\n      \"pmids\": [\"2157286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The HPV E6–E6AP complex functions as a ubiquitin-protein ligase (E3) that ubiquitinates p53, targeting it for proteasomal degradation; E6AP itself possesses intrinsic ubiquitin ligase activity independent of E6.\",\n      \"method\": \"In vitro ubiquitination reconstitution with purified E1, E2, E6, E6-AP and p53\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — fully reconstituted in vitro E3 ligase activity with purified components; >2000 citations\",\n      \"pmids\": [\"8221889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"MDM2 protein binds directly to p53 in vitro; the MDM2 gene is amplified in over one-third of human sarcomas, providing a mechanism for functional inactivation of p53 without mutation of TP53 itself.\",\n      \"method\": \"In vitro binding of recombinant proteins; Southern blot/gene amplification analysis of sarcoma samples\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein binding plus genomic amplification in tumors; >1900 citations\",\n      \"pmids\": [\"1614537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Crystal structure of the MDM2 N-terminal domain bound to the p53 transactivation domain peptide revealed that p53 binds as an amphipathic α-helix inserting into a deep hydrophobic cleft on MDM2; three p53 residues (Phe19, Trp23, Leu26) make critical contacts, and this surface overlaps with p53's transactivation domain, explaining how MDM2 inhibits p53 transcriptional activity.\",\n      \"method\": \"X-ray crystallography of MDM2–p53 peptide complex\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure defining the molecular interface; >1800 citations\",\n      \"pmids\": [\"8875929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MDM2 is a ubiquitin ligase (E3) that polyubiquitinates p53 in the presence of E1 and UbcH5 (E2); a cysteine residue in the C-terminus of MDM2 is essential for this E3 activity, providing the primary mechanism for p53 proteasomal degradation in cells lacking viral E6.\",\n      \"method\": \"In vitro ubiquitination assay with purified recombinant proteins; cysteine mutagenesis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro E3 ligase activity with mutagenesis confirmation; >1600 citations\",\n      \"pmids\": [\"9450543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"DNA damage-induced phosphorylation of p53 at Ser15 (and Ser37) by DNA-PK reduces p53's interaction with MDM2, thereby alleviating MDM2-mediated inhibition of p53 transcriptional activity; this phosphorylation induces a conformational change in p53.\",\n      \"method\": \"In vitro phosphorylation with purified DNA-PK; co-immunoprecipitation; transcription reporter assays in cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay plus cellular validation; >1700 citations\",\n      \"pmids\": [\"9363941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"p53 can be acetylated in vitro and in vivo by the coactivator p300 at C-terminal lysine residues; this acetylation dramatically stimulates p53 sequence-specific DNA-binding activity, indicating a novel activation pathway through acetylation-induced conformational change.\",\n      \"method\": \"In vitro acetylation assay with purified p300 and p53; DNA-binding EMSA; in vivo acetylation detection\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution plus functional DNA-binding assay; >2200 citations\",\n      \"pmids\": [\"9288740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Oncogenic Ras expression in primary human or rodent cells induces a permanent G1 arrest (premature senescence) accompanied by accumulation of p53 and p16INK4a; inactivation of either p53 or p16 prevents this arrest, establishing that p53 is required for Ras-induced oncogene senescence.\",\n      \"method\": \"Retroviral expression of oncogenic Ras in primary cells; genetic inactivation of p53 and p16; cell cycle analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis with KO/KD plus phenotypic readout; >4200 citations\",\n      \"pmids\": [\"9054499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ATM kinase is activated by ionizing radiation and directly phosphorylates p53 at Ser15 in a manganese-dependent manner; ionizing radiation (but not UV) rapidly enhances ATM's p53-directed kinase activity, and phosphorylation of p53 Ser15 is reduced in ataxia telangiectasia cells, establishing ATM as a kinase that phosphorylates p53 in vivo after ionizing radiation.\",\n      \"method\": \"In vitro kinase assay with immunoprecipitated ATM; phosphorylation mapping; ATM-deficient cell lines\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase reconstitution plus genetic validation in AT cells; >1700 citations\",\n      \"pmids\": [\"9733515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"hSIRT1 (hSIR2) binds p53 and deacetylates it in an NAD-dependent manner with specificity for Lys382; wild-type hSIRT1 expression reduces p53 transcriptional activity, while a catalytically inactive mutant potentiates p53-dependent apoptosis and radiosensitivity.\",\n      \"method\": \"Co-immunoprecipitation; in vitro deacetylase assay; transcription reporter assays; catalytic mutant expression\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic assay plus cellular functional validation with catalytic mutant; >2200 citations\",\n      \"pmids\": [\"11672523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HAUSP (herpesvirus-associated ubiquitin-specific protease) was identified by mass spectrometry as a p53-interacting protein; HAUSP specifically deubiquitinates p53 both in vitro and in vivo, stabilizing p53 even in the presence of excess MDM2 and inducing p53-dependent growth repression and apoptosis; a catalytically inactive HAUSP mutant increases p53 ubiquitination and destabilizes p53.\",\n      \"method\": \"Mass spectrometry of affinity-purified p53 complexes; Co-IP; in vitro deubiquitination assay; catalytic point mutant; cell growth/apoptosis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MS identification, reconstituted DUB assay, catalytic mutant, functional rescue; >860 citations\",\n      \"pmids\": [\"11923872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Small-molecule MDM2 antagonists (Nutlins) that bind the p53-binding pocket of MDM2 (confirmed by co-crystal structures) activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and inhibition of tumor xenograft growth in vivo.\",\n      \"method\": \"X-ray crystallography of MDM2–Nutlin complexes; cell-based p53 pathway activation; xenograft tumor growth inhibition\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of inhibitor complex plus in vivo functional validation; >3800 citations\",\n      \"pmids\": [\"14704432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Cytosolic p53 directly activates the proapoptotic Bcl-2 protein Bax in the absence of other proteins, sufficient to permeabilize mitochondria and engage apoptosis; this transcription-independent mechanism operates similarly to BH3-only proteins and also releases Bcl-xL-sequestered proapoptotic factors.\",\n      \"method\": \"In vitro mitochondrial permeabilization assay with purified proteins; cytosolic fractionation; transcription-deficient p53 mutant analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro assay with purified p53 and Bax; transcription-independent mutant confirmation; >1600 citations\",\n      \"pmids\": [\"14963330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"p53 has an alternative internal promoter in intron 3 (conserved from Drosophila to humans) and produces multiple splice variants including p53β and Δ133p53; p53β can enhance p53 target gene expression in a promoter-dependent manner, while Δ133p53 acts as a dominant-negative inhibitor of full-length p53-mediated apoptosis.\",\n      \"method\": \"RT-PCR; reporter assays; antisense inhibition; expression in tumor vs. normal tissue\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional characterization of isoforms with reporter assays and dominant-negative demonstration; >670 citations\",\n      \"pmids\": [\"16131611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"p53 transactivates miR-34a directly after DNA damage; miR-34a expression causes widespread reprogramming of gene expression enriched for cell-cycle, apoptosis, DNA repair, and angiogenesis genes, and promotes apoptosis, establishing miR-34a as a component of the p53 transcriptional network.\",\n      \"method\": \"Global miRNA expression profiling; promoter characterization; p53 ChIP; miR-34a overexpression with gene expression arrays; apoptosis assays\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct p53 binding to miR-34a promoter plus functional consequences; >1600 citations\",\n      \"pmids\": [\"17540599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"USP10, a cytoplasmic deubiquitinase, deubiquitinates p53 and reverses MDM2-induced p53 nuclear export and degradation; after DNA damage, USP10 is stabilized and a fraction translocates to the nucleus to activate p53; ATM phosphorylates USP10 at Thr42 and Ser337 to regulate this translocation and stabilization.\",\n      \"method\": \"Co-IP; in vitro deubiquitination assay; subcellular fractionation; ATM kinase assay; USP10 KD with p53 stability readouts\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro DUB assay, ATM phosphorylation site mapping, localization with functional consequence; >500 citations\",\n      \"pmids\": [\"20096447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"lincRNA-p21 is transcriptionally induced by p53 and serves as a transcriptional repressor in the p53 response; it physically associates with hnRNP-K, and this interaction is required for proper genomic localization of hnRNP-K at repressed genes; lincRNA-p21 knockdown de-represses hundreds of p53-repressed genes and reduces apoptosis.\",\n      \"method\": \"RNA-seq; RIP (RNA immunoprecipitation) for hnRNP-K; lincRNA-p21 knockdown with gene expression profiling; ChIP\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA-protein interaction demonstrated by RIP, genomic localization by ChIP, KD with functional readout; >1700 citations\",\n      \"pmids\": [\"20673990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p53DINP1, a p53-inducible nuclear protein, is required for Ser46 phosphorylation of p53 and for induction of p53AIP1 and apoptosis in response to DNA double-strand breaks; overexpression of p53DINP1 synergizes with DNA damage to enhance Ser46 phosphorylation; the protein complex associated with p53DINP1 can phosphorylate p53 at Ser46, placing p53DINP1 as a cofactor for the Ser46 kinase.\",\n      \"method\": \"Differential display; antisense oligonucleotide inhibition; overexpression; in vitro kinase assay with p53DINP1-associated complex\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinase assay plus antisense KD functional phenotype; single lab but multiple methods\",\n      \"pmids\": [\"11511362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"E2F1, unlike E2F2, specifically signals p53 phosphorylation (modifications resembling DNA damage response) in a p19ARF-independent manner; this phosphorylation is required for E2F1-mediated apoptosis; caffeine (PI3K-related kinase inhibitor) abolishes both p53 phosphorylation and E2F1-mediated apoptosis, and co-expression of a p53 phosphorylation-site mutant compromises apoptosis.\",\n      \"method\": \"Adenoviral expression of E2F1 in p19ARF-null cells; Western blot for phospho-p53; apoptosis assays; caffeine inhibition; phospho-site mutant p53\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis plus pharmacological inhibition and phospho-site mutagenesis; single lab\",\n      \"pmids\": [\"12101227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OTUD5, a deubiquitinase, interacts directly with p53 and deubiquitinates it; OTUD5 is required for rapid activation of p53-dependent transcription and p53-dependent apoptosis in response to DNA damage.\",\n      \"method\": \"Co-IP; in vitro deubiquitination assay; OTUD5 knockdown with p53 ubiquitination and apoptosis readouts\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct DUB assay plus KD functional phenotype; single lab\",\n      \"pmids\": [\"24143256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"USP11, an ubiquitin-specific protease, forms a specific complex with p53 and stabilizes it by deubiquitination; USP11 knockdown markedly attenuates p53 induction in response to DNA damage.\",\n      \"method\": \"Co-IP; deubiquitination assay; USP11 knockdown with p53 stability readout\",\n      \"journal\": \"Journal of Zhejiang University. Science. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP and DUB assay with KD; single lab, limited functional follow-up\",\n      \"pmids\": [\"25471832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"p53 suppresses ferroptosis resistance by repressing SLC7A11 (a key component of the cystine/glutamate antiporter), thereby inhibiting cystine uptake and sensitizing cells to ferroptotic death under ROS stress; an acetylation-defective p53 mutant (3KR) that cannot induce cell-cycle arrest, senescence, or apoptosis retains this SLC7A11-repression activity and tumor suppressive function in xenograft models.\",\n      \"method\": \"ChIP; reporter assays; p53 3KR acetylation mutant; SLC7A11 overexpression rescue; xenograft tumor growth assays; ferroptosis cell death assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic dissection with separation-of-function mutant, ChIP, and in vivo rescue; >2700 citations\",\n      \"pmids\": [\"25799988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NAT10 acetylates p53 at K120 and promotes p53 stabilization by counteracting MDM2; additionally, NAT10 promotes MDM2 degradation via its intrinsic E3 ligase activity; after DNA damage, NAT10 translocates from nucleolus to nucleoplasm to activate p53-mediated cell cycle control and apoptosis.\",\n      \"method\": \"Co-IP; in vitro acetylation assay; in vitro ubiquitination assay; subcellular fractionation/localization; KD with p53 target gene expression and cell cycle/apoptosis readouts\",\n      \"journal\": \"EMBO Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical assays (acetylation, ubiquitination) plus localization with functional consequence; single lab\",\n      \"pmids\": [\"26882543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of TP53 and RB1 function enables lineage plasticity in prostate cancer through increased SOX2 expression, allowing tumor cells to shift from AR-dependent luminal to AR-independent basal-like phenotype; restoration of TP53 and RB1 function or SOX2 inhibition reverses this plasticity and restores drug sensitivity.\",\n      \"method\": \"In vitro and in vivo human prostate cancer models with TP53/RB1 knockout/restoration; SOX2 knockdown; lineage marker analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function/rescue in both cell and animal models with defined molecular mechanism; >870 citations\",\n      \"pmids\": [\"28059768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The p53 isoform Δ133p53β promotes cancer cell invasion and EMT (epithelial-to-mesenchymal transition) regardless of TP53 mutation status; depletion of endogenous Δ133p53β prevents invasiveness without affecting full-length mutant p53 expression, explaining why wild-type TP53 can promote invasion in some contexts.\",\n      \"method\": \"Isoform-specific siRNA depletion; overexpression; invasion assays; EMT marker analysis in breast and colon cell lines\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific KD with defined phenotypic readout; multiple cell lines; single lab\",\n      \"pmids\": [\"27630122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"p53 is modified by β-hydroxybutyrylation (Kbhb) at Lys120, Lys319, and Lys370, catalyzed by CBP; p53 Kbhb results in reduced acetylation levels and decreased expression of p53 target genes (p21, PUMA), as well as reduced cell growth arrest and apoptosis; this mechanism is activated by elevated β-hydroxybutyrate (BHB) during starvation.\",\n      \"method\": \"Mass spectrometry identification of modification sites; CBP in vitro Kbhb assay; BHB treatment of cells and fasted mouse thymus; p53 target gene expression; apoptosis/growth arrest assays\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel PTM identified by MS, catalytic enzyme identified, functional consequence shown in cells and in vivo; single lab\",\n      \"pmids\": [\"30858356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FBW7α targets p53 for proteasomal degradation via Lys-48-linked polyubiquitylation at Lys-132; this requires phosphorylation of p53 at Ser33 (by GSK3β) and Ser37 (by DNA-PK) creating a phosphodegron that enhances p53 binding to FBW7α; FBW7α-mediated degradation occurs during and after DNA double-strand breaks, and its abrogation enhances p53 tumor-suppressive function.\",\n      \"method\": \"Co-IP; in vitro ubiquitination assay; phospho-site mutagenesis; kinase inhibitor treatments; FBW7α domain mutants; DNA damage assays\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphodegron identified with mutagenesis, E3 activity reconstituted, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"31346036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZDHHC1 palmitoyltransferase palmitoylates p53 at Cys135, Cys176, and Cys275; this palmitoylation is required for nuclear translocation of p53; p53 in turn recruits DNMT3A to the ZDHHC1 promoter, creating an epigenetic feedback loop that silences ZDHHC1.\",\n      \"method\": \"Acyl-RAC palmitoylation assay; site-directed mutagenesis of cysteine residues; nuclear fractionation; ChIP for DNMT3A\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — palmitoylation identified and sites mapped by mutagenesis, nuclear localization consequence shown, feedback loop by ChIP; single lab\",\n      \"pmids\": [\"34282274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"p53 transactivates the MKP1 phosphatase through two p53 responsive elements—one in the second intron and a newly identified one in the third exon of MKP1; both elements bind p53 in vitro (gel shift) and in vivo (ChIP), and mutation of either element reduces reporter activity ~50% while loss of both completely abolishes p53-dependent MKP1 transcription.\",\n      \"method\": \"Reporter gene assays; EMSA (gel shift); ChIP; site-directed mutagenesis of p53 responsive elements\",\n      \"journal\": \"Cancer Biology & Therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct p53 binding to regulatory elements shown by EMSA and ChIP with mutagenesis; single lab\",\n      \"pmids\": [\"15611668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A mouse model of the human TP53 R181C germline mutation (p53 R178C knockin) revealed a novel lipolytic activity of p53: mutant mice are lean with increased lipolysis and fatty acid metabolism in white adipose tissue; ChIP-seq showed mutant p53 bound and transactivated the ADRB3 (Beta-3-Adrenergic Receptor) gene, which promotes lipolysis.\",\n      \"method\": \"Knockin mouse model; body composition analysis; gene expression profiling; ChIP-seq\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq direct binding evidence plus in vivo metabolic phenotype in knockin model; single lab\",\n      \"pmids\": [\"31968253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The African-centric TP53 Y107H variant is structurally similar to wild-type p53 (by NMR and crystal structure) but is specifically impaired for transactivation of a small subset of target genes including PADI4; PADI4 (a citrullinating enzyme) is itself tumor suppressive and requires an intact immune system for this function; a p53-PADI4 gene signature predicts cancer survival and response to immune-checkpoint inhibitors.\",\n      \"method\": \"NMR structure; crystal structure; transcriptional reporter assays; Y107H knockin mouse tumor models; PADI4 KO mouse; immune depletion experiments\",\n      \"journal\": \"Cancer Discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — structural and functional characterization with in vivo tumor models and immune validation; multiple orthogonal methods\",\n      \"pmids\": [\"37140445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"An African-specific p53 variant S47 (Pro47Ser) shows selective impairment in transactivating metabolic target genes GLS2 and SCO2 and is markedly defective in inducing ferroptotic cell death; S47 mice develop spontaneous cancers of diverse histological types.\",\n      \"method\": \"Human cell lines and knockin mouse model; p53 target gene expression profiling; cell death assays with multiple genotoxic agents; ferroptosis assays\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional dissection of variant activity in cell lines and in vivo knockin model; single lab\",\n      \"pmids\": [\"27034505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Deoxycholic acid (DCA) suppresses p53 protein levels by stimulating proteasome-mediated degradation via the nuclear export protein CRM1/ERK signaling pathway; this occurs post-transcriptionally (DCA actually induces p53 mRNA) and is blocked by the proteasome inhibitor lactacystin, CRM1 inhibitor leptomycin B, or ERK pathway inhibitors.\",\n      \"method\": \"HCT116 cell line; p53 mRNA vs. protein analysis; proteasome/CRM1/ERK inhibitors; p53 transcriptional activity assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibitor approach without direct reconstitution; single lab with multiple inhibitors\",\n      \"pmids\": [\"11375905\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"p53 (TP53) is a tetrameric transcription factor whose core DNA-binding domain (stabilized by zinc and structured around a β-sandwich scaffold) binds specific response elements to activate or repress target genes governing cell cycle arrest, apoptosis (including direct cytosolic activation of Bax), senescence, ferroptosis (via SLC7A11 repression), and metabolic regulation; its activity is tightly controlled by a web of post-translational modifications—including MDM2-mediated ubiquitination (reversed by deubiquitinases HAUSP, USP10, USP11, OTUD5), p300/CBP-mediated acetylation at C-terminal and K120 lysines (reversed by SIRT1), damage-induced phosphorylation at Ser15/Ser37 by ATM and DNA-PK (disrupting MDM2 binding), and novel modifications including β-hydroxybutyrylation (by CBP) and palmitoylation (by ZDHHC1, required for nuclear localization); MDM2 serves as its primary E3 ligase and transcriptional inhibitor, itself antagonized by Nutlin-class small molecules; multiple isoforms (e.g., Δ133p53β, p53β) arising from alternative promoters differentially modulate full-length p53 activity; and HPV E6 hijacks the cellular E3 ligase E6AP to ubiquitinate and degrade p53 in virally-associated cancers.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TP53 encodes p53, the principal transcription factor governing the cellular response to genotoxic and oncogenic stress, integrating diverse upstream signals into decisions of cell cycle arrest, apoptosis, or metabolic reprogramming. p53 protein levels are tightly controlled by Mdm2-mediated ubiquitination and proteasomal degradation, counterbalanced by multiple deubiquitinases — HAUSP/USP7 directly deubiquitinates p53 even in excess Mdm2 [PMID:11923872], while ATM-phosphorylated USP10 translocates to the nucleus after DNA damage to stabilize p53 [PMID:20096447] — and by an additional phosphodegron-dependent pathway in which GSK3β and DNA-PK phosphorylate p53 to license FBW7α/SCF-mediated K48-linked ubiquitination at Lys-132 [PMID:31346036]. The transcriptional output of p53 is tuned by site-specific modifications — Ser46 phosphorylation gated by the cofactor p53DINP1 switches p53 toward pro-apoptotic targets such as p53AIP1, Noxa, and PUMA [PMID:11511362, PMID:16827804], acetylation at K120 by CBP or NAT10 activates cell cycle arrest and apoptosis [PMID:26882543], while β-hydroxybutyrylation of the same lysine by CBP attenuates these outputs [PMID:30858356] — and its mRNA abundance is regulated post-transcriptionally by the antisense transcript Wrap53 [PMID:19250907] and miR-3151 [PMID:24736457]. Beyond canonical tumor suppression, alternative TP53 isoforms such as Δ133p53β independently promote invasion and EMT [PMID:27630122], and population-specific germline variants (S47, Y107H) selectively impair transactivation of metabolic or immune-related targets (Gls2, Sco2, PADI4) and predispose to spontaneous cancers in mouse models [PMID:27034505, PMID:37140445].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that p53 apoptotic output is gated by a specific cofactor–kinase pathway at Ser46 resolved how DNA damage intensity is decoded into distinct p53 transcriptional programs (arrest vs. apoptosis).\",\n      \"evidence\": \"Differential display cloning of p53DINP1, antisense knockdown and overexpression with in vitro Ser46 kinase assay and apoptosis readout in human cells\",\n      \"pmids\": [\"11511362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The identity of the Ser46 kinase recruited by p53DINP1 was not fully resolved\", \"Whether p53DINP1 functions equivalently across tissue types is unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of HAUSP as the first p53-specific deubiquitinase demonstrated that p53 stability is not solely determined by Mdm2-mediated ubiquitination but is actively counterbalanced by deubiquitination.\",\n      \"evidence\": \"Mass spectrometry of p53-associated factors, in vitro deubiquitination assay, catalytically inactive mutant analysis in human cells\",\n      \"pmids\": [\"11923872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How HAUSP is itself regulated in response to stress was not addressed\", \"Relative contribution of HAUSP vs. other DUBs in vivo remained unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showing that E2F1 activates DNA-damage-like phosphorylation of p53 independently of p19ARF linked oncogene signaling to the p53 post-translational modification code, extending p53 activation beyond classical DNA damage.\",\n      \"evidence\": \"Epistasis in p19ARF-null MEFs, p53 phospho-site mutants, caffeine blockade of PI3K-related kinases with apoptosis readout\",\n      \"pmids\": [\"12101227\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The specific PI3K-related kinase(s) mediating E2F1-induced p53 phosphorylation were not identified\", \"Physiological relevance in non-MEF contexts not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that p53 directly transactivates MKP1 through two distinct responsive elements expanded the p53 target gene repertoire to include MAPK pathway regulators, linking p53 to phosphatase-mediated signaling control.\",\n      \"evidence\": \"ChIP, EMSA, reporter assays with site-directed mutagenesis of intronic and exonic p53 response elements\",\n      \"pmids\": [\"15611668\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of MKP1 induction for cell fate decisions was not fully tested\", \"Whether both elements are utilized across cell types is unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery of an internal promoter in TP53 intron 3 producing functionally distinct isoforms (p53β, Δ133p53) revealed that the TP53 locus encodes multiple proteins with opposing activities, fundamentally complicating the single-gene tumor suppressor model.\",\n      \"evidence\": \"Alternative promoter sequencing, reporter assays, overexpression and knockdown with apoptosis readout in human cells and tissue\",\n      \"pmids\": [\"16131611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative expression and regulation of isoforms across tissues poorly characterized\", \"Mechanism by which Δ133p53 dominantly inhibits full-length p53 not resolved at the structural level\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The p53-S46F gain-of-function mutant demonstrated that Ser46 modification status acts as a molecular switch favoring pro-apoptotic over cell-cycle-arrest targets, refining understanding of the post-translational code that determines p53 transcriptional selectivity.\",\n      \"evidence\": \"Adenoviral transduction, apoptosis assays, luciferase reporters for Noxa/p53AIP1/p21, xenograft model\",\n      \"pmids\": [\"16827804\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for altered promoter selectivity of S46F not determined\", \"Whether S46F phenocopies physiological Ser46 phosphorylation in all contexts is untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of Wrap53 as a natural antisense transcript that stabilizes p53 mRNA via 5′ UTR interaction revealed a previously unknown post-transcriptional layer of p53 regulation, adding RNA-level control to the canonical protein-stability paradigm.\",\n      \"evidence\": \"siRNA knockdown, overexpression, RNA hybrid blockade, qRT-PCR, apoptosis assays in human cells\",\n      \"pmids\": [\"19250907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Wrap53 itself is regulated in response to stress is incompletely characterized\", \"Structural basis of the RNA–RNA interaction not resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that ATM phosphorylates USP10, driving its nuclear translocation and p53 deubiquitination, established a direct signaling axis from DNA damage kinase to cytoplasmic DUB to nuclear p53 stabilization — an activation circuit parallel to Mdm2 inhibition.\",\n      \"evidence\": \"ATM kinase assay, in vitro deubiquitination, subcellular fractionation, USP10 knockdown with phenotypic readout\",\n      \"pmids\": [\"20096447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether USP10 and HAUSP act redundantly or on distinct p53 pools is unresolved\", \"Phosphatases that reverse USP10 phosphorylation are unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"OTUD5 was added as another direct p53 deubiquitinase required for rapid DNA-damage-induced p53 activation, further emphasizing the multi-DUB control architecture of p53 stability.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro deubiquitination assay, knockdown with transcriptional and apoptosis readouts\",\n      \"pmids\": [\"24143256\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No upstream signal controlling OTUD5–p53 interaction identified\", \"Relative contribution compared to HAUSP and USP10 not determined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of miR-3151 as a direct negative regulator of TP53 mRNA via 3′ UTR binding established that p53 abundance is controlled by microRNAs, complementing the Wrap53 antisense mechanism at the mRNA level.\",\n      \"evidence\": \"3′ UTR luciferase reporter, Western blot, overexpression/knockdown with apoptosis and leukemogenesis readouts in mice\",\n      \"pmids\": [\"24736457\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether miR-3151 cooperates with Mdm2-mediated degradation not tested\", \"Regulation of miR-3151 expression in cancer contexts is incomplete\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that Δ133p53β promotes invasion and EMT independently of full-length p53 mutation status demonstrated that TP53-derived isoforms have autonomous oncogenic functions, not merely dominant-negative effects.\",\n      \"evidence\": \"Isoform-specific siRNA knockdown, overexpression, EMT marker analysis, invasion assays across breast and colon cancer cell lines\",\n      \"pmids\": [\"27630122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream transcriptional targets of Δ133p53β driving EMT not fully catalogued\", \"Whether Δ133p53β binds DNA directly or acts via protein interactions is unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"NAT10 was identified as a new p53 K120 acetyltransferase that also degrades Mdm2 via intrinsic E3 ligase activity, revealing a dual-mechanism activator that simultaneously modifies p53 and removes its principal negative regulator.\",\n      \"evidence\": \"In vitro acetylation and E3 ligase assays, subcellular fractionation, knockdown with functional readouts\",\n      \"pmids\": [\"26882543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of NAT10 vs. CBP at K120 under physiological conditions not quantified\", \"Whether NAT10 E3 ligase targets Mdm2 exclusively or also other substrates is unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of CBP-catalyzed β-hydroxybutyrylation at p53 K120/K319/K370 revealed a metabolite-responsive modification that competes with acetylation and attenuates p53 transcriptional activity, linking ketone body metabolism to tumor suppressor function.\",\n      \"evidence\": \"Mass spectrometry site mapping, in vitro acylation with CBP, BHB treatment, gene expression and apoptosis assays in cells and mouse thymus\",\n      \"pmids\": [\"30858356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Erasers (de-β-hydroxybutyrylases) for p53 Kbhb are unknown\", \"In vivo relevance during ketogenic conditions in tumor contexts not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that FBW7α/SCF ubiquitinates p53 at K132 in a phosphodegron-dependent manner (requiring GSK3β at S33 and DNA-PK at S37) established a Mdm2-independent ubiquitin–proteasome pathway for p53 degradation specifically during DNA damage resolution.\",\n      \"evidence\": \"In vitro ubiquitination reconstitution, mutagenesis of phospho-sites and K132, kinase inhibitor experiments, half-life measurements\",\n      \"pmids\": [\"31346036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FBW7α-mediated and Mdm2-mediated degradation are temporally coordinated during damage recovery is unclear\", \"Whether other SCF substrates compete for FBW7α binding during this window is unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ChIP-seq identification of ADRB3 as a direct p53 transcriptional target linked p53 to lipolysis regulation, extending the functional repertoire of p53 from tumor suppression to systemic metabolic control.\",\n      \"evidence\": \"p53 R178C knockin mouse model, ChIP-seq demonstrating p53 occupancy at ADRB3, metabolic phenotyping\",\n      \"pmids\": [\"31968253\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether wild-type p53 regulates ADRB3 to the same extent as the R181C variant is unclear\", \"Mechanism by which p53 at ADRB3 locus controls adipose tissue lipolysis not molecularly detailed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of ZDHHC1-mediated palmitoylation at C135/C176/C275 as a requirement for p53 nuclear import revealed a lipid modification step in p53 activation, and a reciprocal feedback loop through p53-directed DNMT3A silencing of ZDHHC1.\",\n      \"evidence\": \"Mass spectrometry, mutagenesis, nuclear/cytoplasmic fractionation, ChIP at ZDHHC1 promoter, methylation analysis\",\n      \"pmids\": [\"34282274\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"De-palmitoylating enzymes for p53 are unidentified\", \"Whether palmitoylation is a general requirement or tissue/context-specific is unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Structural and functional analysis of the African-specific Y107H variant demonstrated that a single p53 point mutation can selectively impair transactivation of specific targets (PADI4) while leaving global p53 function intact, revealing a precision-loss-of-function mechanism for cancer predisposition that requires immune competence.\",\n      \"evidence\": \"Crystal structure and NMR of Y107H, transcriptional profiling, colony assays, knockin mouse cancer model, PADI4 functional assays\",\n      \"pmids\": [\"37140445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PADI4-mediated tumor suppression engages the immune system mechanistically is unresolved\", \"Whether other population-specific TP53 variants show similar selective transactivation defects is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The relative contributions of multiple deubiquitinases (HAUSP, USP10, OTUD5), ubiquitin ligases (Mdm2, FBW7α, E6/E6AP), and competing acyl modifications (acetylation vs. β-hydroxybutyrylation at K120) to p53 output in defined physiological contexts remain unintegrated into a quantitative model of p53 regulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No quantitative model integrating multiple DUBs and E3 ligases in a single cell type exists\", \"How metabolic state (e.g. ketosis) tunes p53 modification balance in vivo is poorly understood\", \"The functional interplay between mRNA-level control (Wrap53, miR-3151) and protein-level control (ubiquitination, modifications) has not been addressed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [10, 15, 18]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 10, 15, 16, 18, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 5, 13]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [5, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 6, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 9, 16, 19]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 15, 18]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [1, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [18, 19, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"MDM2\",\n      \"USP7\",\n      \"USP10\",\n      \"NAT10\",\n      \"FBXW7\",\n      \"CREBBP\",\n      \"ZDHHC1\",\n      \"DNMT3A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"p53 is a tetrameric transcription factor and master tumor suppressor that integrates diverse stress signals to execute cell cycle arrest, apoptosis, senescence, and ferroptosis. Its core DNA-binding domain, a zinc-stabilized β-sandwich scaffold, recognizes specific response elements in target genes including p21, PUMA, miR-34a, SLC7A11, and MKP1, while also functioning in a transcription-independent manner by directly activating the proapoptotic protein Bax at mitochondria [PMID:8023157, PMID:14963330, PMID:25799988, PMID:17540599]. p53 stability and activity are governed by an elaborate network of post-translational modifications: MDM2-mediated ubiquitination targets p53 for proteasomal degradation, counteracted by deubiquitinases HAUSP and USP10; DNA-damage-induced phosphorylation at Ser15 by ATM and DNA-PK disrupts MDM2 binding; and p300/CBP-mediated acetylation at C-terminal lysines enhances DNA binding, while SIRT1-mediated deacetylation attenuates transcriptional output [PMID:9450543, PMID:11923872, PMID:20096447, PMID:9733515, PMID:9288740, PMID:11672523]. TP53 somatic mutations cluster in the conserved DNA-contact and structural residues of the core domain and are found across virtually all human tumor types; viral inactivation occurs through the HPV E6–E6AP ubiquitin ligase complex, while MDM2 gene amplification provides a non-mutational route to p53 inactivation, and alternative p53 isoforms such as Δ133p53 can dominantly antagonize full-length p53 function [PMID:1905840, PMID:2157286, PMID:1614537, PMID:16131611].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing that viral oncoproteins physically target p53 answered how DNA tumor viruses disable tumor suppression, linking p53 to the mechanism of HPV-driven carcinogenesis.\",\n      \"evidence\": \"Co-immunoprecipitation demonstrating direct HPV E6–p53 binding\",\n      \"pmids\": [\"2157286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of E6-mediated p53 degradation not yet defined\", \"Whether E6 recruits a cellular ubiquitin ligase unknown\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Systematic sequencing of TP53 across tumor types revealed that mutations concentrate in four conserved DNA-binding domain regions with carcinogen-specific spectra, establishing TP53 as the most broadly mutated gene in human cancer.\",\n      \"evidence\": \"Direct DNA sequencing of TP53 in diverse tumor panels\",\n      \"pmids\": [\"1905840\", \"2531845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why specific codons are preferential hotspots not structurally explained\", \"Functional consequence of individual mutations not biochemically tested\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Discovery that MDM2 binds p53 directly and is amplified in sarcomas identified the principal cellular negative regulator of p53, explaining how tumors inactivate p53 without TP53 mutation.\",\n      \"evidence\": \"In vitro binding of recombinant proteins; Southern blot showing MDM2 amplification in sarcomas\",\n      \"pmids\": [\"1614537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MDM2 degrades p53 or only inhibits transactivation not distinguished\", \"Structural basis of binding unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Reconstitution of the E6–E6AP ubiquitin ligase complex degrading p53 established the first defined proteolytic pathway targeting p53 and revealed E6AP as a cellular E3 ligase co-opted by HPV.\",\n      \"evidence\": \"In vitro ubiquitination with purified E1, E2, E6, E6AP, and p53\",\n      \"pmids\": [\"8221889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether analogous cellular E3 ligases target p53 in the absence of virus unknown\", \"In vivo degradation kinetics not measured\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"The crystal structure of the p53 core domain bound to DNA explained why cancer mutations cluster at DNA-contact residues and zinc-coordinating positions, transforming mutational data into a structural framework.\",\n      \"evidence\": \"X-ray crystallography at 2.2 Å resolution\",\n      \"pmids\": [\"8023157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length tetrameric p53 not resolved\", \"How mutations alter protein stability versus DNA contact not quantified\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The MDM2–p53 co-crystal structure revealed that p53's transactivation helix inserts into a hydrophobic cleft on MDM2, explaining how MDM2 simultaneously blocks transcription and enabling structure-based drug design.\",\n      \"evidence\": \"X-ray crystallography of MDM2 N-terminal domain bound to p53 peptide\",\n      \"pmids\": [\"8875929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length MDM2–p53 complex structure unavailable\", \"Whether disrupting this interface suffices for p53 activation in vivo untested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"A suite of discoveries established the core regulatory logic of p53 activation: MDM2 was shown to be a direct E3 ubiquitin ligase for p53; DNA-damage-induced phosphorylation at Ser15/Ser37 by DNA-PK disrupts MDM2 binding; and p300-mediated acetylation of C-terminal lysines stimulates DNA binding — collectively defining the PTM code that toggles p53 between latent and active states.\",\n      \"evidence\": \"In vitro ubiquitination with MDM2 and cysteine mutagenesis; in vitro DNA-PK phosphorylation with MDM2 co-IP; in vitro p300 acetylation with EMSA\",\n      \"pmids\": [\"9450543\", \"9363941\", \"9288740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the in vivo kinase for Ser15 (ATM vs DNA-PK) not resolved\", \"Interplay between phosphorylation and acetylation not defined\", \"Whether acetylation is required or merely potentiating in vivo unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that oncogenic Ras triggers p53-dependent premature senescence in primary cells established senescence as a bona fide p53-mediated tumor-suppressive output distinct from apoptosis.\",\n      \"evidence\": \"Retroviral Ras expression in primary cells with p53 genetic inactivation\",\n      \"pmids\": [\"9054499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific p53 target genes mediating senescence not identified\", \"Relative contribution of p53 versus p16 not fully dissected\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of ATM as the ionizing-radiation-activated kinase that phosphorylates p53 Ser15 in vivo resolved the upstream kinase question and linked p53 activation to the DNA double-strand break signaling cascade.\",\n      \"evidence\": \"In vitro kinase assay with immunoprecipitated ATM; reduced Ser15 phosphorylation in ATM-deficient cells\",\n      \"pmids\": [\"9733515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ATM phosphorylates p53 directly or through intermediary kinases like Chk2 not fully resolved\", \"UV-induced p53 activation pathway still undefined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Discovery that SIRT1 deacetylates p53 at Lys382 in an NAD-dependent manner established a metabolically-regulated brake on p53 activity, linking cellular metabolic state to tumor suppression.\",\n      \"evidence\": \"Co-IP; in vitro NAD-dependent deacetylase assay; catalytic-dead mutant enhancing p53-dependent apoptosis\",\n      \"pmids\": [\"11672523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological contexts where SIRT1–p53 axis is rate-limiting not defined\", \"Whether other sirtuins contribute to p53 deacetylation unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of HAUSP as a deubiquitinase that stabilizes p53 even in the presence of excess MDM2 revealed that p53 levels are set by a balance between ubiquitination and deubiquitination rather than by MDM2 alone.\",\n      \"evidence\": \"Mass spectrometry of p53 complexes; in vitro DUB assay; catalytic-dead mutant destabilizing p53\",\n      \"pmids\": [\"11923872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HAUSP also deubiquitinates MDM2 (creating a regulatory triangle) not addressed\", \"Signals that regulate HAUSP activity unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Two breakthroughs expanded p53's functional repertoire and therapeutic tractability: reconstitution of transcription-independent apoptosis via direct p53–Bax interaction at mitochondria, and development of Nutlin small molecules that displace p53 from MDM2 to reactivate the pathway in wild-type TP53 tumors.\",\n      \"evidence\": \"Purified p53–Bax mitochondrial permeabilization assay; Nutlin–MDM2 co-crystal structure with xenograft tumor inhibition\",\n      \"pmids\": [\"14963330\", \"14704432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of cytosolic versus nuclear p53 to apoptosis in vivo not quantified\", \"Nutlin efficacy in patients not yet demonstrated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery of alternative p53 isoforms (p53β, Δ133p53) from an internal promoter revealed that the TP53 locus encodes functionally opposing proteins, with Δ133p53 acting as a dominant-negative inhibitor of full-length p53.\",\n      \"evidence\": \"RT-PCR; reporter assays; antisense inhibition showing dominant-negative effects\",\n      \"pmids\": [\"16131611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative abundance and tissue specificity of isoforms in normal tissues not systematically mapped\", \"Whether isoforms form mixed tetramers with full-length p53 not structurally resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of miR-34a as a direct p53 transcriptional target that mediates widespread gene repression extended the p53 network into non-coding RNA-based gene regulation.\",\n      \"evidence\": \"ChIP showing p53 binding at miR-34a promoter; miR-34a overexpression with expression arrays and apoptosis readout\",\n      \"pmids\": [\"17540599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether miR-34a is required for p53-mediated tumor suppression in vivo not tested genetically\", \"Other p53-regulated miRNAs not systematically catalogued\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"USP10 was identified as a cytoplasmic deubiquitinase that reverses MDM2-mediated p53 ubiquitination and translocates to the nucleus upon ATM-dependent phosphorylation, adding a spatially regulated layer to p53 stabilization after DNA damage.\",\n      \"evidence\": \"In vitro DUB assay; ATM phosphorylation site mapping; subcellular fractionation; USP10 knockdown\",\n      \"pmids\": [\"20096447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether USP10 and HAUSP act redundantly or on distinct p53 pools not determined\", \"Structural basis of USP10–p53 interaction unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that p53 induces the long non-coding RNA lincRNA-p21, which recruits hnRNP-K to repress hundreds of genes, established a mechanism for p53-mediated transcriptional repression through lncRNA scaffolding.\",\n      \"evidence\": \"RNA-seq; RNA immunoprecipitation for hnRNP-K; lincRNA-p21 knockdown with gene expression profiling\",\n      \"pmids\": [\"20673990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether lincRNA-p21 acts in cis or trans genome-wide not resolved\", \"Contribution of lincRNA-p21 to tumor suppression in vivo not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstration that p53 represses SLC7A11 to promote ferroptosis — and that an acetylation-defective p53 mutant retaining this activity still suppresses tumors — identified ferroptosis as a p53-dependent tumor-suppressive program separable from canonical cell-cycle arrest and apoptosis.\",\n      \"evidence\": \"ChIP; p53 3KR acetylation-defective mutant; SLC7A11 overexpression rescue; xenograft assays; ferroptosis death assays\",\n      \"pmids\": [\"25799988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ferroptosis is the critical tumor-suppressive output in specific tissue contexts not defined\", \"Mechanism of SLC7A11 transcriptional repression (co-repressor identity) not determined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Studies of the African-specific p53 S47 variant revealed selective loss of metabolic target gene induction and ferroptosis, while combined TP53/RB1 loss was shown to enable lineage plasticity in prostate cancer through SOX2, expanding p53's tumor-suppressive roles to metabolic regulation and cell fate determination.\",\n      \"evidence\": \"S47 knockin mice with spontaneous tumors and ferroptosis assays; TP53/RB1 knockout prostate cancer models with SOX2 analysis\",\n      \"pmids\": [\"27034505\", \"28059768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S47 variant affects immune-mediated tumor suppression not tested\", \"Mechanistic basis for p53/Rb cooperation in lineage plasticity not molecularly defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of β-hydroxybutyrylation of p53 by CBP at Lys120/319/370 during ketosis, competing with acetylation and attenuating transcriptional activity, revealed a metabolite-driven mechanism linking fasting to p53 dampening.\",\n      \"evidence\": \"Mass spectrometry; CBP in vitro Kbhb assay; BHB-treated cells and fasted mouse thymus; p53 target gene expression\",\n      \"pmids\": [\"30858356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological significance of Kbhb versus acetylation competition not quantified at endogenous levels\", \"Whether Kbhb has independent signaling functions beyond blocking acetylation unknown\", \"Independent replication of Kbhb modification pending\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that ZDHHC1-mediated palmitoylation at three cysteines in the p53 core domain is required for nuclear translocation introduced lipid modification as a regulator of p53 localization, with a reciprocal epigenetic feedback loop silencing ZDHHC1 through p53-recruited DNMT3A.\",\n      \"evidence\": \"Acyl-RAC assay; cysteine mutagenesis; nuclear fractionation; ChIP for DNMT3A at ZDHHC1 promoter\",\n      \"pmids\": [\"34282274\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether palmitoylation is constitutive or signal-regulated not defined\", \"Impact on DNA-binding domain structure (palmitoylated cysteines overlap with zinc-coordinating region) not assessed\", \"Independent replication of palmitoylation requirement for nuclear entry pending\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Structural and functional characterization of the African-centric Y107H variant revealed selective loss of PADI4 transactivation and an immune-dependent tumor-suppressive axis, uncovering a p53–PADI4–immune surveillance pathway relevant to immunotherapy response.\",\n      \"evidence\": \"NMR and crystal structure of Y107H; Y107H knockin mouse tumor models; PADI4 KO mice; immune depletion\",\n      \"pmids\": [\"37140445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PADI4-mediated citrullination connects to immune recognition not molecularly defined\", \"Whether the p53-PADI4 signature generalizes beyond the cohorts tested unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include: how the relative contributions of p53's diverse outputs (arrest, apoptosis, senescence, ferroptosis, immune surveillance) are determined in a tissue- and context-specific manner; the full structural basis of tetrameric p53 on chromatin with co-regulators; and how the many post-translational modifications are integrated combinatorially to specify target gene selection.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length p53 tetramer structure on DNA with cofactors not resolved\", \"Combinatorial PTM code for target gene selectivity not decoded\", \"Tissue-specific determinants of p53 output choice not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 8, 16, 23, 30, 32]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [8, 9, 15, 16, 18, 23, 25, 30, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17, 24, 29]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [14, 17]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 14, 23, 33]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [9, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 10, 17, 20]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [7, 10, 17]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [16, 18, 23, 30, 32]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 3, 4, 25, 33]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [9, 23, 27]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [32]}\n    ],\n    \"complexes\": [\n      \"p53 homotetramer\"\n    ],\n    \"partners\": [\n      \"MDM2\",\n      \"HAUSP\",\n      \"USP10\",\n      \"SIRT1\",\n      \"EP300\",\n      \"BAX\",\n      \"TP53BP2\",\n      \"UBE3A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}